Year |
Citation |
Score |
2023 |
Kazi A, Ranjan A, Kumar M V V, Agianian B, Garcia Chavez M, Vudatha V, Wang R, Vangipurapu R, Chen L, Kennedy P, Subramanian K, Quirke JCK, Beato F, Underwood P, Fleming JB, ... ... Sebti SM, et al. Discovery of KRB-456, a KRAS G12D switch-I/II allosteric pocket binder that inhibits the growth of pancreatic cancer patient-derived tumors. Cancer Research Communications. PMID 38051103 DOI: 10.1158/2767-9764.CRC-23-0222 |
0.314 |
|
2021 |
Zhou L, Pei X, Zhang Y, Ning Y, Li L, Hu X, Chalasani SL, Sharma K, Nkwocha J, Yu J, Bandyopadhyay D, Sebti SM, Grant S. Chk1 inhibition potently blocks STAT3 tyrosine705 phosphorylation, DNA binding activity, and activation of downstream targets in human multiple myeloma cells. Molecular Cancer Research : McR. PMID 34782371 DOI: 10.1158/1541-7786.MCR-21-0366 |
0.341 |
|
2020 |
Yang H, Xiang S, Kazi A, Sebti SM. The GTPase KRAS suppresses the P53 tumor suppressor by activating the NRF2-regulated antioxidant defense system in cancer cells. The Journal of Biological Chemistry. PMID 32001619 DOI: 10.1074/Jbc.Ra119.011930 |
0.379 |
|
2019 |
Sebti SM, Kazi A, Xiang S, Yang H, Chen L, Kennedy P, Ayaz M, Fletcher S, Cummings C, Lawrence HR, Beato F, Kang Y, Kim MP, Delitto A, Underwood PW, et al. Dual farnesyl and geranylgeranyl transferase inhibitor thwarts mutant KRAS-driven patient-derived pancreatic tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31227505 DOI: 10.1158/1078-0432.Ccr-18-3399 |
0.302 |
|
2019 |
Kazi A, Xiang S, Yang H, Chen L, Kennedy P, Ayaz M, Fletcher S, Cummings C, Lawrence H, Beato F, Yang Y, Kim MP, Delitto A, Underwood P, Fleming JB, ... ... Sebti SM, et al. Abstract 3088: Farnesyl/geranylgeranyl transferase dual inhibitor thwarts mutant KRas-driven patient-derived pancreatic tumors Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-3088 |
0.344 |
|
2018 |
Vangipurapu R, Chen L, Kennedy P, Morrison KC, Hergenrother PJ, Sebti SM. Abstract 1669: Identification of mutant KRas-Raf-1 binding disruptors Cancer Research. 78: 1669-1669. DOI: 10.1158/1538-7445.Am2018-1669 |
0.334 |
|
2017 |
Kuchay S, Giorgi C, Simoneschi D, Pagan J, Missiroli S, Saraf A, Florens L, Washburn MP, Collazo-Lorduy A, Castillo-Martin M, Cordon-Cardo C, Sebti SM, Pinton P, Pagano M. PTEN counteracts FBXL2 to promote IP3R3- and Ca(2+)-mediated apoptosis limiting tumour growth. Nature. PMID 28614300 DOI: 10.1038/Nature22965 |
0.33 |
|
2017 |
Nishimura S, Mishra-Gorur K, Park J, Surovtseva YV, Sebti SM, Levchenko A, Louvi A, Gunel M. Combined HMG-COA reductase and prenylation inhibition in treatment of CCM. Proceedings of the National Academy of Sciences of the United States of America. PMID 28500274 DOI: 10.1073/Pnas.1702942114 |
0.308 |
|
2017 |
Husain K, Centeno BA, Coppola D, Trevino J, Sebti SM, Malafa MP. d-Tocotrienol, a natural form of vitamin E, inhibits pancreatic cancer stem-like cells and prevents pancreatic cancer metastasis. Oncotarget. PMID 28404939 DOI: 10.18632/Oncotarget.15767 |
0.394 |
|
2017 |
Betts BC, Veerapathran A, Pidala J, Yang H, Horna P, Walton K, Cubitt CL, Gunawan S, Lawrence HR, Lawrence NJ, Sebti SM, Anasetti C. Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function. Science Translational Medicine. 9. PMID 28077684 DOI: 10.1126/Scitranslmed.Aai8269 |
0.343 |
|
2017 |
Husain K, Sebti SM, Malafa MP. Abstract 1098: Delta-tocotrienol chemosensitizes human pancreatic tumor metastasis to gemcitabine targeting cancer stem cells Cancer Research. 77: 1098-1098. DOI: 10.1158/1538-7445.Am2017-1098 |
0.388 |
|
2016 |
Husain K, Coppola D, Sebti SM, Malafa MP. Abstract 3839: Vitamin E delta-tocotrienol targets human colon cancer stem cells and inhibits colon cancer metastasis and induces apoptosis Cancer Research. 76: 3839-3839. DOI: 10.1158/1538-7445.Am2016-3839 |
0.385 |
|
2015 |
Wang C, Husain K, Zhang A, Centeno BA, Chen DT, Tong Z, Sebti SM, Malafa MP. EGR-1/Bax pathway plays a role in vitamin E δ-tocotrienol-induced apoptosis in pancreatic cancer cells. The Journal of Nutritional Biochemistry. 26: 797-807. PMID 25997867 DOI: 10.1016/J.Jnutbio.2015.02.008 |
0.37 |
|
2015 |
Betts BC, Sagatys EM, Veerapathran A, Lloyd MC, Beato F, Lawrence HR, Yue B, Kim J, Sebti SM, Anasetti C, Pidala J. CD4+ T cell STAT3 phosphorylation precedes acute GVHD, and subsequent Th17 tissue invasion correlates with GVHD severity and therapeutic response. Journal of Leukocyte Biology. 97: 807-19. PMID 25663681 DOI: 10.1189/Jlb.5A1114-532Rr |
0.333 |
|
2015 |
Li R, Cheng C, Balasis ME, Liu Y, Garner TP, Daniel KG, Li J, Qin Y, Gavathiotis E, Sebti SM. Design, synthesis and evaluation of marinopyrrole derivatives as selective inhibitors of Mcl-1 binding to pro-apoptotic Bim and dual Mcl-1/Bcl-xL inhibitors. European Journal of Medicinal Chemistry. 90: 315-31. PMID 25437618 DOI: 10.1016/J.Ejmech.2014.11.035 |
0.417 |
|
2015 |
Husain K, Sebti SM, Malafa MP. Abstract 4383: Vitamin E delta-tocotrienol inhibits metastasis and targets cancer stem cell signaling in human pancreatic cancer Cancer Research. 75: 4383-4383. DOI: 10.1158/1538-7445.Am2015-4383 |
0.387 |
|
2015 |
Yang H, Emmons MF, Cubitt C, Shain K, Coppola D, Sullivan D, Lynch CC, Hazlehurst L, Sebti SM. Abstract 2605: The geranylgeranyltransferase I inhibitor GGTI-2418 suppresses multiple myeloma malignancy in the 5TMG1 mouse model Cancer Research. 75: 2605-2605. DOI: 10.1158/1538-7445.Am2015-2605 |
0.357 |
|
2015 |
Kennedy PC, Guilanotti MC, LsVoi T, Sebti SM. Abstract 2580: Screening of a mixture-based synthetic combinatorial library identifies small molecules that inhibit the ability of GTP to displace mant-GDP from mutant G12D KRas Cancer Research. 75: 2580-2580. DOI: 10.1158/1538-7445.Am2015-2580 |
0.392 |
|
2015 |
Berndt N, Zhang X, Jiang RHY, Sebti SM. Abstract 2153: Kinome inhibitor screen identifies kinase inhibitors that inhibit selectively the survival of mutant K-Ras-dependent human cancer cells Cancer Research. 75: 2153-2153. DOI: 10.1158/1538-7445.Am2015-2153 |
0.476 |
|
2014 |
Tecleab A, Zhang X, Sebti SM. Ral GTPase down-regulation stabilizes and reactivates p53 to inhibit malignant transformation. The Journal of Biological Chemistry. 289: 31296-309. PMID 25210032 DOI: 10.1074/Jbc.M114.565796 |
0.794 |
|
2014 |
Kim YB, Kang CW, Ranatunga S, Yang H, Sebti SM, Del Valle JR. Imidazo[1,2-a]pyridine-based peptidomimetics as inhibitors of Akt. Bioorganic & Medicinal Chemistry Letters. 24: 4650-3. PMID 25205195 DOI: 10.1016/J.Bmcl.2014.08.040 |
0.388 |
|
2014 |
Cheng C, Liu Y, Balasis ME, Garner TP, Li J, Simmons NL, Berndt N, Song H, Pan L, Qin Y, Nicolaou KC, Gavathiotis E, Sebti SM, Li R. Marinopyrrole derivatives with sulfide spacers as selective disruptors of Mcl-1 binding to pro-apoptotic protein Bim. Marine Drugs. 12: 4311-25. PMID 25076060 DOI: 10.3390/Md12084311 |
0.379 |
|
2014 |
Zhang X, Blaskovich MA, Forinash KD, Sebti SM. Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours British Journal of Cancer. 111: 894-902. PMID 24983364 DOI: 10.1038/Bjc.2014.349 |
0.398 |
|
2014 |
Teng P, Zhang X, Wu H, Qiao Q, Sebti SM, Cai J. Identification of novel inhibitors that disrupt STAT3-DNA interaction from a γ-AApeptide OBOC combinatorial library. Chemical Communications (Cambridge, England). 50: 8739-42. PMID 24964402 DOI: 10.1039/C4Cc03909B |
0.333 |
|
2014 |
Yang H, Lawrence HR, Kazi A, Gevariya H, Patel R, Luo Y, Rix U, Schonbrunn E, Lawrence NJ, Sebti SM. Dual aurora a and jak2 kinase blockade effectively suppresses malignant transformation Oncotarget. 5: 2947-2961. PMID 24930769 DOI: 10.18632/Oncotarget.1615 |
0.486 |
|
2014 |
Cheng C, Liu Y, Balasis ME, Simmons NL, Li J, Song H, Pan L, Qin Y, Nicolaou KC, Sebti SM, Li R. Cyclic marinopyrrole derivatives as disruptors of Mcl-1 and Bcl-x(L) binding to Bim. Marine Drugs. 12: 1335-48. PMID 24608970 DOI: 10.3390/Md12031335 |
0.312 |
|
2014 |
Kazi A, Ozcan S, Tecleab A, Sun Y, Lawrence HR, Sebti SM. Discovery of PI-1840, a novel noncovalent and rapidly reversible proteasome inhibitor with anti-tumor activity Journal of Biological Chemistry. 289: 11906-11915. PMID 24570003 DOI: 10.1074/Jbc.M113.533950 |
0.806 |
|
2014 |
Patel RA, Liu Y, Wang B, Li R, Sebti SM. Identification of novel ROCK inhibitors with anti-migratory and anti-invasive activities Oncogene. 33: 550-555. PMID 23396364 DOI: 10.1038/Onc.2012.634 |
0.463 |
|
2014 |
Betts BC, Veerapathran A, Beato F, Lawrence HR, Sebti SM, Pidala JA, Anasetti C. CD4+ T-Cell STAT3 Activity Is Increased before Acute Graft-Versus-Host Disease Onset and Its Pharmacologic Inhibition Selectively Controls Alloresponses Blood. 124: 3819-3819. DOI: 10.1182/Blood.V124.21.3819.3819 |
0.314 |
|
2014 |
Aslamuzzaman K, Zhang X, Luo Y, Patel R, Fletcher S, Cummings C, Lawrence H, Hamilton A, Sebti SM. Abstract B35: Dual inhibitors of FT and GGT-1 as novel therapeutic agents for K-Ras-dependent tumors Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Rasonc14-B35 |
0.421 |
|
2014 |
Sebti SM, Berndt N, Patel R, Yang H, Balasis M. Abstract 4522: Akt2 and acid ceramidase cooperate to induce malignant transformation Cancer Research. 74: 4522-4522. DOI: 10.1158/1538-7445.Am2014-4522 |
0.452 |
|
2014 |
Zhang X, Blaskovich MA, Forinash KD, Sebti SM. Abstract 3802: Withacnistin blocks binding of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumors in vivo Cancer Research. 74: 3802-3802. DOI: 10.1158/1538-7445.Am2014-3802 |
0.412 |
|
2014 |
Sebti SM, Kazi A, Ozcan S, Tecleab AG, Sun Y, Lawrence H. Abstract 1810: PI-1840, a novel non-covalent and rapidly reversible proteasome inhibitor with anti-tumor activity Cancer Research. 74: 1810-1810. DOI: 10.1158/1538-7445.Am2014-1810 |
0.473 |
|
2014 |
Sebti SM, Yang H, Lawrence H, Kazi A, Gervaria H, Patel R, Luo Y, Rix U, Schonbrunn E, Lawrence N. Abstract 1750: Combined blockade of Aurora A and JAK2 kinase is highly effective at inhibiting malignant transformation Cancer Research. 74: 1750-1750. DOI: 10.1158/1538-7445.Am2014-1750 |
0.498 |
|
2014 |
Husain K, Sebti SM, Malafa MP. Abstract 1699: Delta-tocotrienol potentiates the antitumor activity of standard chemotherapy with gemcitabine and abraxane in metastatic pancreatic cancer Cancer Research. 74: 1699-1699. DOI: 10.1158/1538-7445.Am2014-1699 |
0.436 |
|
2014 |
Blaskovich MA, Luo Y, Ge Y, Sebti SM, Lawrence HR, Lawrence NJ, Springett GM. Abstract 1640: A novel small molecule inhibitor of lysophosphatidic acid acyltransferase-beta inhibits pancreatic cancer cell proliferation and mTOR signaling Cancer Research. 74: 1640-1640. DOI: 10.1158/1538-7445.Am2014-1640 |
0.402 |
|
2013 |
Blaskovich MA, Yendluri V, Lawrence HR, Lawrence NJ, Sebti SM, Springett GM. Lysophosphatidic acid acyltransferase beta regulates mTOR signaling. Plos One. 8. PMID 24205284 DOI: 10.1371/Journal.Pone.0078632 |
0.341 |
|
2013 |
Treviño JG, Verma M, Singh S, Pillai S, Zhang D, Pernazza D, Sebti SM, Lawrence NJ, Centeno BA, Chellappan SP. Selective disruption of rb-raf-1 kinase interaction inhibits pancreatic adenocarcinoma growth irrespective of gemcitabine sensitivity. Molecular Cancer Therapeutics. 12: 2722-34. PMID 24107447 DOI: 10.1158/1535-7163.Mct-12-0719 |
0.454 |
|
2013 |
Urlam MK, Pireddu R, Ge Y, Zhang X, Sun Y, Lawrence HR, Guida WC, Sebti SM, Lawrence NJ. Development of new N-Arylbenzamides as STAT3 Dimerization Inhibitors. Medchemcomm. 4: 932-941. PMID 24073326 DOI: 10.1039/C3Md20323A |
0.302 |
|
2013 |
Sampath D, Malik A, Plunkett W, Nowak B, Williams B, Burton M, Verstovsek S, Faderl S, Garcia-Manero G, List AF, Sebti S, Kantarjian HM, Ravandi F, Lancet JE. Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. Leukemia Research. 37: 1461-7. PMID 23993427 DOI: 10.1016/J.Leukres.2013.07.034 |
0.403 |
|
2013 |
Husain K, Centeno BA, Chen DT, Hingorani SR, Sebti SM, Malafa MP. Vitamin E δ-tocotrienol prolongs survival in the LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) transgenic mouse model of pancreatic cancer. Cancer Prevention Research (Philadelphia, Pa.). 6: 1074-83. PMID 23963802 DOI: 10.1158/1940-6207.Capr-13-0157 |
0.356 |
|
2013 |
Almhanna K, Cubitt CL, Zhang S, Kazim S, Husain K, Sullivan D, Sebti S, Malafa M. MK-2206, an Akt inhibitor, enhances carboplatinum/paclitaxel efficacy in gastric cancer cell lines. Cancer Biology & Therapy. 14: 932-6. PMID 23917345 DOI: 10.4161/Cbt.25939 |
0.348 |
|
2013 |
Berndt N, Patel R, Yang H, Balasis ME, Sebti SM. Akt2 and acid ceramidase cooperate to induce cell invasion and resistance to apoptosis. Cell Cycle (Georgetown, Tex.). 12: 2024-32. PMID 23777806 DOI: 10.4161/Cc.25043 |
0.446 |
|
2013 |
Schonbrunn E, Betzi S, Alam R, Martin MP, Becker A, Han H, Francis R, Chakrasali R, Jakkaraj S, Kazi A, Sebti SM, Cubitt CL, Gebhard AW, Hazlehurst LA, Tash JS, et al. Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases. Journal of Medicinal Chemistry. 56: 3768-82. PMID 23600925 DOI: 10.1021/Jm301234K |
0.395 |
|
2013 |
Ozcan S, Kazi A, Marsilio F, Fang B, Guida WC, Koomen J, Lawrence HR, Sebti SM. Oxadiazole-isopropylamides as potent and noncovalent proteasome inhibitors Journal of Medicinal Chemistry. 56: 3783-3805. PMID 23547706 DOI: 10.1021/Jm400221D |
0.335 |
|
2013 |
Hodul PJ, Dong Y, Husain K, Pimiento JM, Chen J, Zhang A, Francois R, Pledger WJ, Coppola D, Sebti SM, Chen DT, Malafa MP. Vitamin E δ-tocotrienol induces p27(Kip1)-dependent cell-cycle arrest in pancreatic cancer cells via an E2F-1-dependent mechanism. Plos One. 8: e52526. PMID 23393547 DOI: 10.1371/Journal.Pone.0052526 |
0.45 |
|
2013 |
Tecleab A, Sebti SM. Depletion of K-Ras promotes proteasome degradation of survivin. Cell Cycle (Georgetown, Tex.). 12: 522-32. PMID 23324341 DOI: 10.4161/Cc.23407 |
0.777 |
|
2013 |
Husain K, Centeno BA, Chen DT, Fulp WJ, Perez M, Zhang Lee G, Luetteke N, Hingorani SR, Sebti SM, Malafa MP. Prolonged survival and delayed progression of pancreatic intraepithelial neoplasia in LSL-KrasG12D/+;Pdx-1-Cre mice by vitamin E δ-tocotrienol. Carcinogenesis. 34: 858-63. PMID 23302291 DOI: 10.1093/Carcin/Bgt002 |
0.341 |
|
2013 |
Ucar DA, Magis AT, He DH, Lawrence NJ, Sebti SM, Kurenova E, Zajac-Kaye M, Zhang J, Hochwald SN. Inhibiting the interaction of cMET and IGF-1R with FAK effectively reduces growth of pancreatic cancer cells in vitro and in vivo. Anti-Cancer Agents in Medicinal Chemistry. 13: 595-602. PMID 23272972 DOI: 10.2174/1871520611313040009 |
0.438 |
|
2013 |
Tecleab A, Zhang X, Sebti SM. Abstract 767: RalGTPase regulation of p53 and its contribution to malignant transformation. Cancer Research. 73: 767-767. DOI: 10.1158/1538-7445.Am2013-767 |
0.754 |
|
2013 |
Patel RA, Lui Y, Wang B, Li R, Sebti SM. Abstract 5556: Discovery of RKI-18, a small molecule that inhibits Rho kinases 1 and 2, migration and invasion of human tumors. Cancer Research. 73: 5556-5556. DOI: 10.1158/1538-7445.Am2013-5556 |
0.482 |
|
2013 |
Zhang X, Sun Y, Pireddu R, Yang H, Urlam MK, Lawrence HR, Guida WC, Lawrence NJ, Sebti SM. Abstract 3254: Discovery of S3I-1757, a STAT3-STAT3 dimerization disruptor that inhibits STAT3 activity, tumor survival, migration and invasion. Cancer Research. 73: 3254-3254. DOI: 10.1158/1538-7445.Am2013-3254 |
0.392 |
|
2013 |
Blaskovich MA, Gevariya H, Lawrence NJ, Sebti S, Springett G. Abstract 2470: Identification and evaluation of small molecule inhibitors of lysophosphatidic acid acyltransferase-beta. Cancer Research. 73: 2470-2470. DOI: 10.1158/1538-7445.Am2013-2470 |
0.362 |
|
2013 |
Husain K, Centeno B, Perez M, Dung-Tsa C, Sebti SM, Malafa MP. Abstract 2070: Natural vitamin E delta-tocotrienol combined with gemcitabine prolongs the survival, induces apoptosis, inhibits tumor growth, angiogenesis and oncogenic signaling in a transgenic mouse model of pancreatic cancer. Cancer Research. 73: 2070-2070. DOI: 10.1158/1538-7445.Am2013-2070 |
0.398 |
|
2012 |
Pireddu R, Forinash KD, Sun NN, Martin MP, Sung SS, Alexander B, Zhu JY, Guida WC, Schönbrunn E, Sebti SM, Lawrence NJ. Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2). Medchemcomm. 3: 699-709. PMID 23275831 DOI: 10.1039/C2Md00320A |
0.397 |
|
2012 |
Gajewski TF, Salama AK, Niedzwiecki D, Johnson J, Linette G, Bucher C, Blaskovich MA, Sebti SM, Haluska F. Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104). Journal of Translational Medicine. 10: 246. PMID 23228035 DOI: 10.1200/Jco.2006.24.18_Suppl.8014 |
0.377 |
|
2012 |
Kim YB, Balasis ME, Doi K, Berndt N, DuBoulay C, Hu CC, Guida W, Wang HG, Sebti SM, Del Valle JR. Synthesis and evaluation of substituted hexahydronaphthalenes as novel inhibitors of the Mcl-1/BimBH3 interaction. Bioorganic & Medicinal Chemistry Letters. 22: 5961-5. PMID 22901384 DOI: 10.1016/J.Bmcl.2012.07.050 |
0.398 |
|
2012 |
Ucar DA, Kurenova E, Garrett TJ, Cance WG, Nyberg C, Cox A, Massoll N, Ostrov DA, Lawrence N, Sebti SM, Zajac-Kaye M, Hochwald SN. Disruption of the protein interaction between FAK and IGF-1R inhibits melanoma tumor growth. Cell Cycle (Georgetown, Tex.). 11: 3250-9. PMID 22894899 DOI: 10.1093/Carcin/Bgr115 |
0.41 |
|
2012 |
Patel RA, Forinash KD, Pireddu R, Sun Y, Sun N, Martin MP, Schönbrunn E, Lawrence NJ, Sebti SM. RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer. Cancer Research. 72: 5025-34. PMID 22846914 DOI: 10.1158/0008-5472.Can-12-0954 |
0.453 |
|
2012 |
Lawrence HR, Martin MP, Luo Y, Pireddu R, Yang H, Gevariya H, Ozcan S, Zhu JY, Kendig R, Rodriguez M, Elias R, Cheng JQ, Sebti SM, Schonbrunn E, Lawrence NJ. Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors. Journal of Medicinal Chemistry. 55: 7392-416. PMID 22803810 DOI: 10.1021/Jm300334D |
0.366 |
|
2012 |
Caceres G, Robey RW, Sokol L, McGraw KL, Clark J, Lawrence NJ, Sebti SM, Wiese M, List AF. HG-829 is a potent noncompetitive inhibitor of the ATP-binding cassette multidrug resistance transporter ABCB1. Cancer Research. 72: 4204-13. PMID 22761337 DOI: 10.1158/0008-5472.Can-12-0743 |
0.341 |
|
2012 |
Cheng F, Wang H, Horna P, Wang Z, Shah B, Sahakian E, Woan KV, Villagra A, Pinilla-Ibarz J, Sebti S, Smith M, Tao J, Sotomayor EM. Stat3 inhibition augments the immunogenicity of B-cell lymphoma cells, leading to effective antitumor immunity. Cancer Research. 72: 4440-8. PMID 22728650 DOI: 10.1158/0008-5472.Can-11-3619 |
0.323 |
|
2012 |
Ginestier C, Monville F, Wicinski J, Cabaud O, Cervera N, Josselin E, Finetti P, Guille A, Larderet G, Viens P, Sebti S, Bertucci F, Birnbaum D, Charafe-Jauffret E. Mevalonate Metabolism Regulates Basal Breast Cancer Stem Cells and Is a Potential Therapeutic Target Stem Cells. 30: 1327-1337. PMID 22605458 DOI: 10.1002/Stem.1122 |
0.375 |
|
2012 |
Doi K, Li R, Sung SS, Wu H, Liu Y, Manieri W, Krishnegowda G, Awwad A, Dewey A, Liu X, Amin S, Cheng C, Qin Y, Schonbrunn E, Daughdrill G, ... ... Sebti S, et al. Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. The Journal of Biological Chemistry. 287: 10224-35. PMID 22311987 DOI: 10.1074/Jbc.M111.334532 |
0.374 |
|
2012 |
Win-Piazza H, Schneeberger VE, Chen L, Pernazza D, Lawrence HR, Sebti SM, Lawrence NJ, Wu J. Enhanced anti-melanoma efficacy of interferon alfa-2b via inhibition of Shp2. Cancer Letters. 320: 81-5. PMID 22306001 DOI: 10.1016/J.Canlet.2012.01.034 |
0.369 |
|
2012 |
Li R, Martin MP, Liu Y, Wang B, Patel RA, Zhu JY, Sun N, Pireddu R, Lawrence NJ, Li J, Haura EB, Sung SS, Guida WC, Schonbrunn E, Sebti SM. Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors. Journal of Medicinal Chemistry. 55: 2474-8. PMID 22272748 DOI: 10.1021/Jm201289R |
0.343 |
|
2012 |
Martin MP, Zhu JY, Lawrence HR, Pireddu R, Luo Y, Alam R, Ozcan S, Sebti SM, Lawrence NJ, Schönbrunn E. A novel mechanism by which small molecule inhibitors induce the DFG flip in Aurora A. Acs Chemical Biology. 7: 698-706. PMID 22248356 DOI: 10.1021/Cb200508B |
0.388 |
|
2012 |
Ge Y, Kazi A, Marsilio F, Luo Y, Jain S, Brooks W, Daniel KG, Guida WC, Sebti SM, Lawrence HR. Discovery and synthesis of hydronaphthoquinones as novel proteasome inhibitors. Journal of Medicinal Chemistry. 55: 1978-98. PMID 22220566 DOI: 10.1021/Jm201118H |
0.352 |
|
2012 |
Davis R, Pillai S, Lawrence N, Sebti S, Chellappan SP. TNF-α-mediated proliferation of vascular smooth muscle cells involves Raf-1-mediated inactivation of Rb and transcription of E2F1-regulated genes. Cell Cycle (Georgetown, Tex.). 11: 109-18. PMID 22185776 DOI: 10.4161/cc.11.1.18473 |
0.303 |
|
2012 |
Johnson JL, Pillai S, Pernazza D, Sebti SM, Lawrence NJ, Chellappan SP. Regulation of matrix metalloproteinase genes by E2F transcription factors: Rb-Raf-1 interaction as a novel target for metastatic disease. Cancer Research. 72: 516-26. PMID 22086850 DOI: 10.1158/0008-5472.Can-11-2647 |
0.307 |
|
2012 |
Pireddu R, Forinash K, Sun NN, Martin MP, Sung S, Alexander B, Zhu J, Guida WC, Schönbrunn E, Sebti SM, Lawrence NJ. Abstract 3904: Pyridylthiazole-based ureas as inhibitors of Rho-associated protein kinases Cancer Research. 72: 3904-3904. DOI: 10.1158/1538-7445.Am2012-3904 |
0.466 |
|
2012 |
Lawrence HR, Martin MP, Luo Y, Pireddu R, Gevariya H, Ozcan S, Zhu J, Rodriguez M, Elias R, Yang H, Sebti SM, Schonbrunn E, Lawrence NJ. Abstract 3902: Development of Aurora A inhibitors withortho-halophenyl substituted pyrimidines: Unusual potency, SAR and X-ray crystallography studies. Cancer Research. 72: 3902-3902. DOI: 10.1158/1538-7445.Am2012-3902 |
0.394 |
|
2012 |
Ozcan S, Kazi A, Sun NN, Daniel K, Guida WC, Lawrence HR, Sebti SM. Abstract 3894: Discovery, synthesis and SAR studies of a novel nonpeptidic reversible proteosome inhibitor with low nano-molar chymotrypsin like activity Cancer Research. 72: 3894-3894. DOI: 10.1158/1538-7445.Am2012-3894 |
0.419 |
|
2012 |
Patel RA, Forinash KD, Pireddu R, Sun Y, Martin MP, Zhu J, Alexander BG, Schonbrunn E, Lawrence NJ, Sebti SM. Abstract 2942: RKI-1447, a potent ROCK inhibitor with anti-tumor and anti-invasive activities in breast cancer Cancer Research. 72: 2942-2942. DOI: 10.1158/1538-7445.Am2012-2942 |
0.431 |
|
2012 |
Ge Y, Lawrence HR, Chen L, Scott LM, Sebti SM, Lawrence NJ, Wu J. Abstract 2912: Development of potent SHP2 inhibitors forin vivostudies Cancer Research. 72: 2912-2912. DOI: 10.1158/1538-7445.Am2012-2912 |
0.447 |
|
2012 |
Kazi A, Ozcan S, Lawrence H, Sebti SM. Abstract 2778: Development of non-covalent reversible proteasome inhibitors Cancer Research. 72: 2778-2778. DOI: 10.1158/1538-7445.Am2012-2778 |
0.472 |
|
2012 |
Blaskovich M, Gevariya H, Lawrence NJ, Sebti SM, Springett G. Abstract 1854: Lysophosphatidic Acid Acyltransferase-Beta contributes to proliferation and anchorage-independent growth in pancreatic adenocarcinoma Cancer Research. 72: 1854-1854. DOI: 10.1158/1538-7445.Am2012-1854 |
0.369 |
|
2012 |
Husain K, Centeno B, Perez M, Lee G, Kazim S, Chen D, Sebti S, Malafa M. Abstract 1613: Delta-tocotrienol delays the progression of pancreatic intraepithelial neoplasia (PanIN) lesions in a conditional KrasG12D mouse model Cancer Research. 72: 1613-1613. DOI: 10.1158/1538-7445.Am2012-1613 |
0.35 |
|
2011 |
Berndt N, Sebti SM. Measurement of protein farnesylation and geranylgeranylation in vitro, in cultured cells and in biopsies, and the effects of prenyl transferase inhibitors. Nature Protocols. 6: 1775-91. PMID 22036881 DOI: 10.1038/Nprot.2011.387 |
0.341 |
|
2011 |
Husain K, Francois RA, Yamauchi T, Perez M, Sebti SM, Malafa MP. Vitamin E δ-tocotrienol augments the antitumor activity of gemcitabine and suppresses constitutive NF-κB activation in pancreatic cancer. Molecular Cancer Therapeutics. 10: 2363-72. PMID 21971120 DOI: 10.1158/1535-7163.Mct-11-0424 |
0.374 |
|
2011 |
Balasis ME, Forinash KD, Chen YA, Fulp WJ, Coppola D, Hamilton AD, Cheng JQ, Sebti SM. Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2852-62. PMID 21536547 DOI: 10.1158/1078-0432.Ccr-10-2544 |
0.452 |
|
2011 |
O'Neil BH, Goff LW, Kauh JS, Strosberg JR, Bekaii-Saab TS, Lee RM, Kazi A, Moore DT, Learoyd M, Lush RM, Sebti SM, Sullivan DM. Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2350-6. PMID 21519015 DOI: 10.1200/Jco.2010.33.9432 |
0.321 |
|
2011 |
Lancet JE, Duong VH, Winton EF, Stuart RK, Burton M, Zhang S, Cubitt C, Blaskovich MA, Wright JJ, Sebti S, Sullivan DM. A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 1140-6. PMID 21233404 DOI: 10.1158/1078-0432.Ccr-10-1878 |
0.319 |
|
2011 |
Scott LM, Chen L, Daniel KG, Brooks WH, Guida WC, Lawrence HR, Sebti SM, Lawrence NJ, Wu J. Shp2 protein tyrosine phosphatase inhibitor activity of estramustine phosphate and its triterpenoid analogs. Bioorganic & Medicinal Chemistry Letters. 21: 730-3. PMID 21193311 DOI: 10.1016/J.Bmcl.2010.11.117 |
0.394 |
|
2011 |
Garrett CR, Coppola D, Wenham RM, Cubitt CL, Neuger AM, Frost TJ, Lush RM, Sullivan DM, Cheng JQ, Sebti SM. Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. Investigational New Drugs. 29: 1381-9. PMID 20644979 DOI: 10.1007/S10637-010-9479-2 |
0.433 |
|
2011 |
Kazi A, Luo Y, Berndt N, Fletcher S, Cummings C, Lawrence H, Hamilton AD, Sebti SM. Abstract 620: Development of a dual protein farnesyltransferase -geranylgeranyltransferase-I inhibitor with antitumor activity against human cancer cells Cancer Research. 71: 620-620. DOI: 10.1158/1538-7445.Am2011-620 |
0.512 |
|
2011 |
Tecleab A, Sebti SM. Abstract 3844: K-Ras is required for maintaining survivin protein stability in human cancer cells harboring mutant but not wild type K-Ras Cancer Research. 71: 3844-3844. DOI: 10.1158/1538-7445.Am2011-3844 |
0.781 |
|
2011 |
Pireddu R, Lawrence HR, Martin MP, Betzi S, Yip R, Yang H, Sun NN, Cheng JQ, Schonbrunn E, Sebti SM, Lawrence NJ. Abstract 3253: Novel oxindole inhibitors of Aurora A kinase: Structure based hit-to-lead approach Cancer Research. 71: 3253-3253. DOI: 10.1158/1538-7445.Am2011-3253 |
0.426 |
|
2011 |
Luo Y, Martin M, Kendig R, Pireddu R, Yang H, Betzi S, Books W, Yu H, Schonbrunn E, Lawrence N, Cheng J, Sebti S, Lawrence H. Abstract 3252: Potent Aurora kinase inhibitors based on a pyrimidine scaffold: Synthesis, SAR and X-ray crystallography studies Cancer Research. 71: 3252-3252. DOI: 10.1158/1538-7445.Am2011-3252 |
0.405 |
|
2011 |
Gevariya H, Ortiz ED, Chen L, Daniel K, Lawrence HR, Guida WC, Sebti SM, Wu J, Lawrence NJ. Abstract 3248: New inhibitors of the Shp2 phosphatase Cancer Research. 71: 3248-3248. DOI: 10.1158/1538-7445.Am2011-3248 |
0.483 |
|
2011 |
Alexander BG, Pireddu R, Sun NN, Yu H, Forinash KD, Martin MP, Schonbrunn E, Guida WC, Sebti SM, Lawrence NJ. Abstract 3243: Discovery of novel Rho kinase inhibitors: Hit generation and lead optimization Cancer Research. 71: 3243-3243. DOI: 10.1158/1538-7445.Am2011-3243 |
0.394 |
|
2011 |
Pernazza D, Li X, Lawrence HR, Guida WC, DuBoulay CJ, Watts S, Sebti SM, Chen J, Lawrence NJ. Abstract 3242: New chemical tools for disrupting the MDM2/p53 protein-protein interaction: Identification, synthesis and biological evaluation of a novel class of MDM2/p53 inhibitors Cancer Research. 71: 3242-3242. DOI: 10.1158/1538-7445.Am2011-3242 |
0.418 |
|
2011 |
Scott LM, Chen L, Daniel KG, Urlam MK, Brooks WH, Guida WC, Lawrence HR, Sebti SM, Lawrence NJ, Wu J. Abstract 3239: Shp2 inhibitor activity of estramustine phosphate and its triterpenoid analogues Cancer Research. 71: 3239-3239. DOI: 10.1158/1538-7445.Am2011-3239 |
0.43 |
|
2011 |
Treviño JG, Verma M, Singh S, Pireddu R, Sebti S, Lawrence N, Chellappan SP. Abstract 2590: Selective disruption of Rb-Raf-1 kinase interaction is a suitable therapeutic option for pancreatic adenocarcinoma Cancer Research. 71: 2590-2590. DOI: 10.1158/1538-7445.Am2011-2590 |
0.319 |
|
2011 |
Verma M, Johnson J, Kovacs M, Singh S, Wu X, Lawrence N, Sebti S, Chellappan S. Abstract 2108: New analogues of benzyl-isothiourea showed Rb-Raf disruption and anti-cancer activity Cancer Research. 71: 2108-2108. DOI: 10.1158/1538-7445.Am2011-2108 |
0.476 |
|
2011 |
Blaskovich MA, Coppola D, Helm J, Sebti S, Springett GM. Abstract 1677: Expression of lysophosphatidic acid acyltransferase-beta in human pancreatic ductal adenocarcinoma Cancer Research. 71: 1677-1677. DOI: 10.1158/1538-7445.Am2011-1677 |
0.316 |
|
2011 |
Ge Y, Ozcan S, Kazi A, Marsilio F, Daniel K, Brooks W, Guida W, Lawrence H, Sebti S. Abstract 1362: Discovery of a novel structural class of compounds: HLM-030376 and its analogs as potent chymotrypsin-like proteasome inhibitors Cancer Research. 71: 1362-1362. DOI: 10.1158/1538-7445.Am2011-1362 |
0.457 |
|
2011 |
Ozcan S, Aslamuzzaman K, Marsilio F, Daniel K, Brooks W, Guida W, Lawrence H, Sebti S. Abstract 1359: Identification of a novel class of compounds as proteasome inhibitors: Synthesis and structure activity relationship studies of PI-1833 library Cancer Research. 71: 1359-1359. DOI: 10.1158/1538-7445.Am2011-1359 |
0.418 |
|
2011 |
Pernazza D, Doi K, Lawrence H, Sebti S, Wang H, Lawrence N. Abstract 1354: New chemical tools for disrupting the Mcl-1/BH3 protein-protein interaction Cancer Research. 71: 1354-1354. DOI: 10.1158/1538-7445.Am2011-1354 |
0.407 |
|
2011 |
Liu Y, Wang B, Patel RA, Sun N, Sung S, Pireddu R, Lawrence NJ, Sebti SM, Li R. Abstract A130: Fragment-based discovery and optimization of Rho kinase inhibitors. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A130 |
0.371 |
|
2011 |
Berndt N, Hamilton AD, Sebti SM. Geranylgeranyltransferase-1 Inhibitors Enzymes. 30: 129-163. DOI: 10.1016/B978-0-12-415922-8.00006-9 |
0.348 |
|
2010 |
Singh S, Davis R, Alamanda V, Pireddu R, Pernazza D, Sebti S, Lawrence N, Chellappan S. Rb-Raf-1 interaction disruptor RRD-251 induces apoptosis in metastatic melanoma cells and synergizes with dacarbazine. Molecular Cancer Therapeutics. 9: 3330-41. PMID 21139044 DOI: 10.1158/1535-7163.Mct-10-0442 |
0.453 |
|
2010 |
Fletcher S, Keaney EP, Cummings CG, Blaskovich MA, Hast MA, Glenn MP, Chang SY, Bucher CJ, Floyd RJ, Katt WP, Gelb MH, Van Voorhis WC, Beese LS, Sebti SM, Hamilton AD. Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agents. Journal of Medicinal Chemistry. 53: 6867-88. PMID 20822181 DOI: 10.1021/Jm1001748 |
0.371 |
|
2010 |
Lawrence HR, Kazi A, Luo Y, Kendig R, Ge Y, Jain S, Daniel K, Santiago D, Guida WC, Sebti SM. Synthesis and biological evaluation of naphthoquinone analogs as a novel class of proteasome inhibitors. Bioorganic & Medicinal Chemistry. 18: 5576-92. PMID 20621484 DOI: 10.1016/J.Bmc.2010.06.038 |
0.351 |
|
2010 |
Chen L, Pernazza D, Scott LM, Lawrence HR, Ren Y, Luo Y, Wu X, Sung SS, Guida WC, Sebti SM, Lawrence NJ, Wu J. Inhibition of cellular Shp2 activity by a methyl ester analog of SPI-112. Biochemical Pharmacology. 80: 801-10. PMID 20510203 DOI: 10.1016/J.Bcp.2010.05.019 |
0.471 |
|
2010 |
Scott LM, Lawrence HR, Sebti SM, Lawrence NJ, Wu J. Targeting protein tyrosine phosphatases for anticancer drug discovery Current Pharmaceutical Design. 16: 1843-1862. PMID 20337577 DOI: 10.2174/138161210791209027 |
0.341 |
|
2010 |
Mahajan K, Coppola D, Challa S, Fang B, Chen YA, Zhu W, Lopez AS, Koomen J, Engelman RW, Rivera C, Muraoka-Cook RS, Cheng JQ, Schönbrunn E, Sebti SM, Earp HS, et al. Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation. Plos One. 5: e9646. PMID 20333297 DOI: 10.1371/Journal.Pone.0009646 |
0.381 |
|
2010 |
Kim D, Sun M, He L, Zhou QH, Chen J, Sun XM, Bepler G, Sebti SM, Cheng JQ. A small molecule inhibits Akt through direct binding to Akt and preventing Akt membrane translocation. The Journal of Biological Chemistry. 285: 8383-94. PMID 20068047 DOI: 10.1074/Jbc.M109.094060 |
0.491 |
|
2010 |
Phan J, Li Z, Kasprzak A, Li B, Sebti S, Guida W, Schönbrunn E, Chen J. Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX. The Journal of Biological Chemistry. 285: 2174-83. PMID 19910468 DOI: 10.1074/Jbc.M109.073056 |
0.374 |
|
2010 |
Caceres G, Robey RW, Sokol L, McGraw KR, Fulp WJ, Clark J, Lawrence NJ, Sebti S, Bates SE, List AF. In Vitro and In Vivo Inhibition of P-Glycoprotein (ABCB1) by a Novel Non-Substrate Compound: HG-829 Blood. 116: 3986-3986. DOI: 10.1182/Blood.V116.21.3986.3986 |
0.368 |
|
2010 |
Lawrence HR, Chen L, Pernazza D, Scott L, Ren Y, Luo Y, Wu X, Shen-Shu S, Guida W, Sebti SM, Lawrence NJ, Wu J. Abstract 761: The development of cell permeable Shp2 PTP inhibitors Cancer Research. 70: 761-761. DOI: 10.1158/1538-7445.Am10-761 |
0.444 |
|
2010 |
Wu X, Scott L, Chen L, Lawrence HR, Luo Y, Sebti SM, Wu J, Lawrence NJ. Abstract 734: Development of small molecule inhibitors of the phosphatase Shp2 by fragment screening Cancer Research. 70: 734-734. DOI: 10.1158/1538-7445.Am10-734 |
0.445 |
|
2010 |
Pireddu R, Sun NN, Yu H, Sung S, Sebti SM, Lawrence NJ. Abstract 733: Synthesis and biological evaluation of inhibitors of Rho protein kinase Cancer Research. 70: 733-733. DOI: 10.1158/1538-7445.Am10-733 |
0.438 |
|
2010 |
Pernazza D, Lawrence HR, Doi K, Sung S, Guida WC, Sebti SM, Wang H, Lawrence NJ. Abstract 732: Targeting the Bcl-2/BH3 protein-protein interaction: Identification, design, and synthesis of new selective inhibitors of the Mcl-1/BH3 interaction Cancer Research. 70: 732-732. DOI: 10.1158/1538-7445.Am10-732 |
0.412 |
|
2010 |
Husain K, Perez M, Sebti S, Malafa M. Abstract 5416: Delta-tocotrienol potentiates antitumor activity of gemcitabine in pancreatic cancer through inhibition of nuclear factor-κB Cancer Research. 70: 5416-5416. DOI: 10.1158/1538-7445.Am10-5416 |
0.423 |
|
2010 |
Berndt N, Yang H, Trinczek B, Zhang Z, Wu B, Lawrence NJ, Pellechia M, Schonbrunn E, Cheng JQ, Sebti SM. Abstract 3680: The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane Cancer Research. 70: 3680-3680. DOI: 10.1158/1538-7445.Am10-3680 |
0.439 |
|
2010 |
Yang H, Wang D, Hamilton AD, Sebti SM. Abstract 3675: Farnesyltransferase inhibitor (FTI) disruption of Rheb/FKBP38 association leads to FKBP38-mediated inactivation of mTOR Cancer Research. 70: 3675-3675. DOI: 10.1158/1538-7445.Am10-3675 |
0.513 |
|
2010 |
Zhang A, Francois RA, Hodul PJ, Husain K, Shivers SC, Coppola D, Sebti SM, Malafa MP. Abstract 222: Inhibition of cellular FLICE-inhibitory protein and induction of death receptor 5 expression is a major component of δ-tocotrienol-induced apoptosis in pancreatic cancer cells Cancer Research. 70: 222-222. DOI: 10.1158/1538-7445.Am10-222 |
0.384 |
|
2010 |
Husain K, Coppola D, Centeno B, Helm J, Kooman J, Lawrence N, Sebti S, Malafa M. Abstract 1612: Validation of CSE1L/hCAS as a potential therapeutic target in pancreatic cancer Cancer Research. 70: 1612-1612. DOI: 10.1158/1538-7445.Am10-1612 |
0.358 |
|
2009 |
O'Neil BH, Williams-Goff LW, Kauh J, Bekaii-Saab T, Strosberg JR, Lee R, Deal AM, Sullivan D, Sebti SM. A phase II study of AZD6244 in advanced or metastatic hepatocellular carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e15574. PMID 27962385 DOI: 10.1200/Jco.2009.27.15_Suppl.E15574 |
0.313 |
|
2009 |
Hong DS, Sebti SM, Newman RA, Blaskovich MA, Ye L, Gagel RF, Moulder S, Wheler JJ, Naing A, Tannir NM, Ng CS, Sherman SI, El Naggar AK, Khan R, Trent J, et al. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 7061-8. PMID 19903778 DOI: 10.1158/1078-0432.Ccr-09-1241 |
0.359 |
|
2009 |
Kazi A, Lawrence H, Guida WC, McLaughlin ML, Springett GM, Berndt N, Yip RM, Sebti SM. Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells. Cell Cycle (Georgetown, Tex.). 8: 1940-51. PMID 19471122 DOI: 10.4161/Cc.8.12.8798 |
0.445 |
|
2009 |
Lawrence HR, Li Z, Yip ML, Sung SS, Lawrence NJ, McLaughlin ML, McManus GJ, Zaworotko MJ, Sebti SM, Chen J, Guida WC. Identification of a disruptor of the MDM2-p53 protein-protein interaction facilitated by high-throughput in silico docking. Bioorganic & Medicinal Chemistry Letters. 19: 3756-9. PMID 19457663 DOI: 10.1016/J.Bmcl.2009.04.124 |
0.324 |
|
2009 |
Hast MA, Fletcher S, Cummings CG, Pusateri EE, Blaskovich MA, Rivas K, Gelb MH, Van Voorhis WC, Sebti SM, Hamilton AD, Beese LS. Structural basis for binding and selectivity of antimalarial and anticancer ethylenediamine inhibitors to protein farnesyltransferase. Chemistry & Biology. 16: 181-92. PMID 19246009 DOI: 10.1016/J.Chembiol.2009.01.014 |
0.37 |
|
2009 |
Kazi A, Carie A, Blaskovich MA, Bucher C, Thai V, Moulder S, Peng H, Carrico D, Pusateri E, Pledger WJ, Berndt N, Hamilton A, Sebti SM. Blockade of protein geranylgeranylation inhibits Cdk2-dependent p27Kip1 phosphorylation on Thr187 and accumulates p27Kip1 in the nucleus: implications for breast cancer therapy. Molecular and Cellular Biology. 29: 2254-63. PMID 19204084 DOI: 10.1128/Mcb.01029-08 |
0.772 |
|
2009 |
Kayser-Bricker KJ, Glenn MP, Lee SH, Sebti SM, Cheng JQ, Hamilton AD. Non-peptidic substrate-mimetic inhibitors of Akt as potential anti-cancer agents. Bioorganic & Medicinal Chemistry. 17: 1764-71. PMID 19179081 DOI: 10.1016/J.Bmc.2008.09.058 |
0.38 |
|
2009 |
Siddiquee KAZ, Gunning PT, Glenn M, Katt WP, Zhang S, Schrock C, Sebti SM, Jove R, Hamilton AD, Turkson J. An oxazole-based small-molecule stat3 inhibitor modulates stat3 stability and processing and induces antitumor cell effects (ACS Chemical Biology (2007) 2, (787-798)) Acs Chemical Biology. 4: 309. DOI: 10.1021/Cb9000684 |
0.341 |
|
2008 |
Chintala L, Kurzrock R, Fu S, Naing A, Wheler JJ, Moulder SL, Newman R, Gagel R, Sebti S, Wright JJ, Hong DS. Phase I study of tipifarnib and sorafenib in patients with biopsiable advanced cancer (NCI protocol 7156). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3593. PMID 27949369 DOI: 10.1200/Jco.2008.26.15_Suppl.3593 |
0.418 |
|
2008 |
Gunning PT, Glenn MP, Siddiquee KA, Katt WP, Masson E, Sebti SM, Turkson J, Hamilton AD. Targeting protein-protein interactions: suppression of Stat3 dimerization with rationally designed small-molecule, nonpeptidic SH2 domain binders. Chembiochem : a European Journal of Chemical Biology. 9: 2800-3. PMID 19006150 DOI: 10.1002/Cbic.200800291 |
0.359 |
|
2008 |
Fletcher S, Cummings CG, Rivas K, Katt WP, Hornéy C, Buckner FS, Chakrabarti D, Sebti SM, Gelb MH, Van Voorhis WC, Hamilton AD. Potent, Plasmodium-selective farnesyltransferase inhibitors that arrest the growth of malaria parasites: structure-activity relationships of ethylenediamine-analogue scaffolds and homology model validation. Journal of Medicinal Chemistry. 51: 5176-97. PMID 18686940 DOI: 10.1021/Jm800113P |
0.373 |
|
2008 |
Lawrence HR, Pireddu R, Chen L, Luo Y, Sung SS, Szymanski AM, Yip ML, Guida WC, Sebti SM, Wu J, Lawrence NJ. Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds. Journal of Medicinal Chemistry. 51: 4948-56. PMID 18680359 DOI: 10.1021/Jm8002526 |
0.379 |
|
2008 |
Gustafsdottir SM, Wennström S, Fredriksson S, Schallmeiner E, Hamilton AD, Sebti SM, Landegren U. Use of proximity ligation to screen for inhibitors of interactions between vascular endothelial growth factor A and its receptors. Clinical Chemistry. 54: 1218-25. PMID 18499900 DOI: 10.1373/Clinchem.2007.099424 |
0.312 |
|
2008 |
Kinkade R, Dasgupta P, Carie A, Pernazza D, Carless M, Pillai S, Lawrence N, Sebti SM, Chellappan S. A small molecule disruptor of Rb/Raf-1 interaction inhibits cell proliferation, angiogenesis, and growth of human tumor xenografts in nude mice. Cancer Research. 68: 3810-8. PMID 18483265 DOI: 10.1158/0008-5472.Can-07-6672 |
0.807 |
|
2008 |
Machida S, Usuba K, Blaskovich MA, Yano A, Harada K, Sebti SM, Kato N, Ohkanda J. Module assembly for protein-surface recognition: geranylgeranyltransferase I bivalent inhibitors for simultaneous targeting of interior and exterior protein surfaces. Chemistry (Weinheim An Der Bergstrasse, Germany). 14: 1392-401. PMID 18200641 DOI: 10.1002/Chem.200701634 |
0.335 |
|
2008 |
Elahi A, Zhang L, Yeatman TJ, Gery S, Sebti S, Shibata D. HPP1-mediated tumor suppression requires activation of STAT1 pathways. International Journal of Cancer. Journal International Du Cancer. 122: 1567-72. PMID 18059030 DOI: 10.1002/Ijc.23202 |
0.404 |
|
2008 |
Ravandi F, Sampath D, Plunkett W, Williams B, Burton M, Verstovsek S, Faderl S, Garcia-Manero G, Alvarez V, Becker MD, List AF, Sebti S, Kantarjian HM, Lancet J. Phase I Study of the Akt-Inhibitor Triciribine Phosphate Monohydrate in Patients with Advanced Hematologic Malignancy Blood. 112: 2987-2987. DOI: 10.1182/Blood.V112.11.2987.2987 |
0.363 |
|
2007 |
Siddiquee KA, Gunning PT, Glenn M, Katt WP, Zhang S, Schrock C, Schroeck C, Sebti SM, Jove R, Hamilton AD, Turkson J. An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. Acs Chemical Biology. 2: 787-98. PMID 18154266 DOI: 10.1021/Cb7001973 |
0.399 |
|
2007 |
Saglam O, Garrett CR, Boulware D, Sayegh Z, Shibata D, Malafa M, Yeatman T, Cheng JQ, Sebti S, Coppola D. Activation of the serine/threonine protein kinase AKT during the progression of colorectal neoplasia. Clinical Colorectal Cancer. 6: 652-6. PMID 17945038 DOI: 10.3816/Ccc.2007.N.034 |
0.417 |
|
2007 |
Falsetti SC, Wang DA, Peng H, Carrico D, Cox AD, Der CJ, Hamilton AD, Sebti SM. Geranylgeranyltransferase I inhibitors target RalB to inhibit anchorage-dependent growth and induce apoptosis and RalA to inhibit anchorage-independent growth. Molecular and Cellular Biology. 27: 8003-14. PMID 17875936 DOI: 10.1128/Mcb.00057-07 |
0.795 |
|
2007 |
Sagatys E, Garrett CR, Boulware D, Kelley S, Malafa M, Cheng JQ, Sebti S, Coppola D. Activation of the serine/threonine protein kinase Akt during the progression of Barrett neoplasia. Human Pathology. 38: 1526-31. PMID 17640711 DOI: 10.1016/J.Humpath.2007.03.003 |
0.407 |
|
2007 |
Siddiquee K, Zhang S, Guida WC, Blaskovich MA, Greedy B, Lawrence HR, Yip ML, Jove R, McLaughlin MM, Lawrence NJ, Sebti SM, Turkson J. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proceedings of the National Academy of Sciences of the United States of America. 104: 7391-6. PMID 17463090 DOI: 10.1073/Pnas.0609757104 |
0.415 |
|
2007 |
Gunning PT, Katt WP, Glenn M, Siddiquee K, Siddique K, Kim JS, Jove R, Sebti SM, Turkson J, Hamilton AD. Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: structural recognition of STAT SH2 domains. Bioorganic & Medicinal Chemistry Letters. 17: 1875-8. PMID 17336521 DOI: 10.1016/J.Bmcl.2007.01.077 |
0.365 |
|
2007 |
Epifano F, Curini M, Genovese S, Blaskovich M, Hamilton A, Sebti SM. Prenyloxyphenylpropanoids as novel lead compounds for the selective inhibition of geranylgeranyl transferase I Bioorganic and Medicinal Chemistry Letters. 17: 2639-2642. PMID 17314046 DOI: 10.1016/J.Bmcl.2007.01.097 |
0.341 |
|
2007 |
Kayser KJ, Glenn MP, Sebti SM, Cheng JQ, Hamilton AD. Modifications of the GSK3beta substrate sequence to produce substrate-mimetic inhibitors of Akt as potential anti-cancer therapeutics. Bioorganic & Medicinal Chemistry Letters. 17: 2068-73. PMID 17276059 DOI: 10.1016/J.Bmcl.2007.01.004 |
0.399 |
|
2007 |
Carie AE, Sebti SM. A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway. Oncogene. 26: 3777-88. PMID 17260025 DOI: 10.1038/Sj.Onc.1210172 |
0.798 |
|
2007 |
Epling-Burnette PK, Sokol L, Moscinski L, Elkabani M, Bai F, Blaskovich M, Zou J, Painter JS, Sebti S, Loughran TP. First Clinical Report of Tipifarnib for the Treatment of T-Large Granular Lymphocyte (LGL) Leukemia. Blood. 110: 3132-3132. DOI: 10.1182/Blood.V110.11.3132.3132 |
0.308 |
|
2007 |
Wang H, Cheng F, Noyes D, Wright K, Mohapatra S, Tao J, Schell M, Sebti S, Smith M, Bhalla K, Pinilla J, Dessureault S, Celis D, Sotomayor EM, Sotomayor IbEM. Enhancement of the Antigen-Presenting Cell Function of Mantle Cell Lymphomas (MCL) by Novel Molecularly Based Immunotherapeutic Strategies. Blood. 110: 2315-2315. DOI: 10.1182/Blood.V110.11.2315.2315 |
0.338 |
|
2007 |
Bai F, Zou J-, Wei S, Painter JS, Blaskovich M, Sebti S, Loughran TP, Epling-Burnette PK. Th2 Polarization Induced by the Farnesyltransferase Inhibitor Tipifarnib (Zarnestra®, R115777) through Suppression of T-bet. Blood. 110: 1331-1331. DOI: 10.1182/Blood.V110.11.1331.1331 |
0.314 |
|
2006 |
Glenn MP, Chang SY, Hornéy C, Rivas K, Yokoyama K, Pusateri EE, Fletcher S, Cummings CG, Buckner FS, Pendyala PR, Chakrabarti D, Sebti SM, Gelb M, Van Voorhis WC, Hamilton AD. Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites. Journal of Medicinal Chemistry. 49: 5710-27. PMID 16970397 DOI: 10.1021/Jm060081V |
0.348 |
|
2006 |
Hu B, Gilkes DM, Farooqi B, Sebti SM, Chen J. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. The Journal of Biological Chemistry. 281: 33030-5. PMID 16905541 DOI: 10.1074/Jbc.C600147200 |
0.411 |
|
2006 |
Sparano JA, Moulder S, Kazi A, Vahdat L, Li T, Pellegrino C, Munster P, Malafa M, Lee D, Hoschander S, Hopkins U, Hershman D, Wright JJ, Sebti SM. Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 3013-8. PMID 16769985 DOI: 10.1200/Jco.2005.04.9114 |
0.323 |
|
2006 |
Zhou H, Wang DA, Baldini L, Ennis E, Jain R, Carie A, Sebti SM, Hamilton AD. Structure-activity studies on a library of potent calix[4]arene-based PDGF antagonists that inhibit PDGF-stimulated PDGFR tyrosine phosphorylation. Organic & Biomolecular Chemistry. 4: 2376-86. PMID 16763682 DOI: 10.1039/B515483A |
0.774 |
|
2006 |
Tang D, Park HJ, Georgescu SP, Sebti SM, Hamilton AD, Galper JB. Simvastatin potentiates tumor necrosis factor alpha-mediated apoptosis of human vascular endothelial cells via the inhibition of the geranylgeranylation of RhoA. Life Sciences. 79: 1484-92. PMID 16740276 DOI: 10.1016/J.Lfs.2006.04.019 |
0.407 |
|
2006 |
Chen L, Sung SS, Yip ML, Lawrence HR, Ren Y, Guida WC, Sebti SM, Lawrence NJ, Wu J. Discovery of a novel shp2 protein tyrosine phosphatase inhibitor. Molecular Pharmacology. 70: 562-70. PMID 16717135 DOI: 10.1124/Mol.106.025536 |
0.471 |
|
2006 |
Donapaty S, Louis S, Horvath E, Kun J, Sebti SM, Malafa MP. RRR-alpha-tocopherol succinate down-regulates oncogenic Ras signaling. Molecular Cancer Therapeutics. 5: 309-16. PMID 16505104 DOI: 10.1158/1535-7163.Mct-05-0330 |
0.437 |
|
2005 |
Guida WC, Hamilton AD, Crotty JW, Sebti SM. Protein farnesyltransferase: flexible docking studies on inhibitors using computational modeling. Journal of Computer-Aided Molecular Design. 19: 871-85. PMID 16607571 DOI: 10.1007/S10822-005-9030-2 |
0.308 |
|
2005 |
Nefedova Y, Nagaraj S, Rosenbauer A, Muro-Cacho C, Sebti SM, Gabrilovich DI. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Research. 65: 9525-35. PMID 16230418 DOI: 10.1158/0008-5472.Can-05-0529 |
0.434 |
|
2005 |
Takahashi Y, Karbowski M, Yamaguchi H, Kazi A, Wu J, Sebti SM, Youle RJ, Wang HG. Loss of Bif-1 suppresses Bax/Bak conformational change and mitochondrial apoptosis. Molecular and Cellular Biology. 25: 9369-82. PMID 16227588 DOI: 10.1128/Mcb.25.21.9369-9382.2005 |
0.364 |
|
2005 |
Nefedova Y, Cheng P, Gilkes D, Blaskovich M, Beg AA, Sebti SM, Gabrilovich DI. Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. Journal of Immunology (Baltimore, Md. : 1950). 175: 4338-46. PMID 16177074 DOI: 10.4049/Jimmunol.175.7.4338 |
0.376 |
|
2005 |
Turkson J, Zhang S, Mora LB, Burns A, Sebti S, Jove R. Platinum compounds that inhibit constitutive stat3 signaling and induce cell cycle arrest and apoptosis of malignant cells Journal of Biological Chemistry. 280: 32979-32988. PMID 16046414 DOI: 10.1074/Jbc.M502694200 |
0.318 |
|
2005 |
Glenn MP, Chang SY, Hucke O, Verlinde CL, Rivas K, Hornéy C, Yokoyama K, Buckner FS, Pendyala PR, Chakrabarti D, Gelb M, Van Voorhis WC, Sebti SM, Hamilton AD. Structurally simple farnesyltransferase inhibitors arrest the growth of malaria parasites. Angewandte Chemie (International Ed. in English). 44: 4903-6. PMID 16007716 DOI: 10.1002/Anie.200500674 |
0.304 |
|
2005 |
Chen L, Yin H, Farooqi B, Sebti S, Hamilton AD, Chen J. p53 alpha-Helix mimetics antagonize p53/MDM2 interaction and activate p53. Molecular Cancer Therapeutics. 4: 1019-25. PMID 15956260 DOI: 10.1158/1535-7163.Mct-04-0342 |
0.358 |
|
2005 |
Nallan L, Bauer KD, Bendale P, Rivas K, Yokoyama K, Hornéy CP, Pendyala PR, Floyd D, Lombardo LJ, Williams DK, Hamilton A, Sebti S, Windsor WT, Weber PC, Buckner FS, et al. Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. Journal of Medicinal Chemistry. 48: 3704-13. PMID 15916422 DOI: 10.1021/Jm0491039 |
0.346 |
|
2005 |
Sun J, Wang DA, Jain RK, Carie A, Paquette S, Ennis E, Blaskovich MA, Baldini L, Coppola D, Hamilton AD, Sebti SM. Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors. Oncogene. 24: 4701-9. PMID 15897913 DOI: 10.1038/Sj.Onc.1208391 |
0.763 |
|
2005 |
Zuckerbraun BS, Barbato JE, Hamilton A, Sebti S, Tzeng E. Inhibition of geranylgeranyltransferase I decreases generation of vascular reactive oxygen species and increases vascular nitric oxide production1 Journal of Surgical Research. 124: 256-263. PMID 15820256 DOI: 10.1016/J.Jss.2004.10.022 |
0.308 |
|
2005 |
Mazières J, Tillement V, Allal C, Clanet C, Bobin L, Chen Z, Sebti SM, Favre G, Pradines A. Geranylgeranylated, but not farnesylated, RhoB suppresses Ras transformation of NIH-3T3 cells. Experimental Cell Research. 304: 354-64. PMID 15748883 DOI: 10.1016/J.Yexcr.2004.10.019 |
0.36 |
|
2005 |
Sun J, Blaskovich MA, Jove R, Livingston SK, Coppola D, Sebti SM. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene. 24: 3236-45. PMID 15735720 DOI: 10.1038/sj.onc.1208470 |
0.336 |
|
2005 |
Zhu K, Gerbino E, Beaupre DM, Mackley PA, Muro-Cacho C, Beam C, Hamilton AD, Lichtenheld MG, Kerr WG, Dalton W, Alsina M, Sebti SM. Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. Blood. 105: 4759-66. PMID 15728126 DOI: 10.1182/Blood-2004-11-4307 |
0.345 |
|
2005 |
Wang DA, Sebti SM. Palmitoylated cysteine 192 is required for RhoB tumor-suppressive and apoptotic activities. The Journal of Biological Chemistry. 280: 19243-9. PMID 15713677 DOI: 10.1074/Jbc.M411472200 |
0.381 |
|
2005 |
Turkson J, Zhang S, Palmer J, Kay H, Stanko J, Mora LB, Sebti S, Yu H, Jove R. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Molecular Cancer Therapeutics. 3: 1533-42. PMID 15634646 |
0.315 |
|
2005 |
Woo JT, Nakagawa H, Krecic AM, Nagai K, Hamilton AD, Sebti SM, Stern PH. Inhibitory effects of mevastatin and a geranylgeranyl transferase I inhibitor (GGTI-2166) on mononuclear osteoclast formation induced by receptor activator of NF kappa B ligand (RANKL) or tumor necrosis factor-alpha (TNF-alpha). Biochemical Pharmacology. 69: 87-95. PMID 15588717 DOI: 10.1016/J.Bcp.2004.08.036 |
0.385 |
|
2005 |
Cheng F, Wang H, Suarez A, Horna P, Sebti S, Sotomayor EM. Cucurbitacins, a Family of Natural Compounds That Effectively Disrupt Stat3 Signaling in Antigen-Presenting Cells (APCs) Are Promising Agents To Overcome Tumor-Induced CD4+ T-Cell Tolerance. Blood. 106: 1485-1485. DOI: 10.1182/Blood.V106.11.1485.1485 |
0.361 |
|
2004 |
Carrico D, Ohkanda J, Kendrick H, Yokoyama K, Blaskovich MA, Bucher CJ, Buckner FS, Van Voorhis WC, Chakrabarti D, Croft SL, Gelb MH, Sebti SM, Hamilton AD. In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability. Bioorganic & Medicinal Chemistry. 12: 6517-26. PMID 15556768 DOI: 10.1016/J.Bmc.2004.09.020 |
0.398 |
|
2004 |
Epling-Burnette PK, Bai F, Wei S, Chaurasia P, Painter JS, Olashaw N, Hamilton A, Sebti S, Djeu JY, Loughran TP. ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL). Oncogene. 23: 9220-9. PMID 15516985 DOI: 10.1038/Sj.Onc.1208122 |
0.384 |
|
2004 |
Dasgupta P, Sun J, Wang S, Fusaro G, Betts V, Padmanabhan J, Sebti SM, Chellappan SP. Disruption of the Rb--Raf-1 interaction inhibits tumor growth and angiogenesis. Molecular and Cellular Biology. 24: 9527-41. PMID 15485920 DOI: 10.1128/Mcb.24.21.9527-9541.2004 |
0.332 |
|
2004 |
Gasparetto M, Gentry T, Sebti S, O'Bryan E, Nimmanapalli R, Blaskovich MA, Bhalla K, Rizzieri D, Haaland P, Dunne J, Smith C. Identification of compounds that enhance the anti-lymphoma activity of rituximab using flow cytometric high-content screening. Journal of Immunological Methods. 292: 59-71. PMID 15350512 DOI: 10.1016/J.Jim.2004.06.003 |
0.312 |
|
2004 |
Paris D, Townsend K, Quadros A, Humphrey J, Sun J, Brem S, Wotoczek-Obadia M, DelleDonne A, Patel N, Obregon DF, Crescentini R, Abdullah L, Coppola D, Rojiani AM, Crawford F, ... Sebti SM, et al. Inhibition of angiogenesis by Abeta peptides. Angiogenesis. 7: 75-85. PMID 15302999 DOI: 10.1023/B:Agen.0000037335.17717.Bf |
0.317 |
|
2004 |
Yang L, Dan HC, Sun M, Liu Q, Sun XM, Feldman RI, Hamilton AD, Polokoff M, Nicosia SV, Herlyn M, Sebti SM, Cheng JQ. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Research. 64: 4394-9. PMID 15231645 DOI: 10.1158/0008-5472.Can-04-0343 |
0.468 |
|
2004 |
Jiang K, Sun J, Cheng J, Djeu JY, Wei S, Sebti S. Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis. Molecular and Cellular Biology. 24: 5565-76. PMID 15169915 DOI: 10.1128/MCB.24.12.5565-5576.2004 |
0.317 |
|
2004 |
Sun J, Blaskovich MA, Jain RK, Delarue F, Paris D, Brem S, Wotoczek-Obadia M, Lin Q, Coppola D, Choi K, Mullan M, Hamilton AD, Sebti SM. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor. Cancer Research. 64: 3586-92. PMID 15150116 DOI: 10.1158/0008-5472.Can-03-2673 |
0.414 |
|
2004 |
Mazieres J, Antonia T, Daste G, Muro-Cacho C, Berchery D, Tillement V, Pradines A, Sebti S, Favre G. Loss of RhoB expression in human lung cancer progression. Clinical Cancer Research. 10: 2742-2750. PMID 15102679 DOI: 10.1158/1078-0432.Ccr-03-0149 |
0.385 |
|
2004 |
Turkson J, Kim JS, Zhang S, Yuan J, Huang M, Glenn M, Haura E, Sebti S, Hamilton AD, Jove R. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Molecular Cancer Therapeutics. 3: 261-9. PMID 15026546 |
0.342 |
|
2004 |
Dan HC, Jiang K, Coppola D, Hamilton A, Nicosia SV, Sebti SM, Cheng JQ. Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis. Oncogene. 23: 706-15. PMID 14737105 DOI: 10.1038/Sj.Onc.1207171 |
0.486 |
|
2004 |
Alsina M, Fonseca R, Wilson EF, Belle AN, Gerbino E, Price-Troska T, Overton RM, Ahmann G, Bruzek LM, Adjei AA, Kaufmann SH, Wright JJ, Sullivan D, Djulbegovic B, Cantor AB, ... ... Sebti SM, et al. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood. 103: 3271-7. PMID 14726402 DOI: 10.1182/Blood-2003-08-2764 |
0.415 |
|
2004 |
Ohkanda J, Buckner FS, Lockman JW, Yokoyama K, Carrico D, Eastman R, de Luca-Fradley K, Davies W, Croft SL, Van Voorhis WC, Gelb MH, Sebti SM, Hamilton AD. Design and synthesis of peptidomimetic protein farnesyltransferase inhibitors as anti-Trypanosoma brucei agents. Journal of Medicinal Chemistry. 47: 432-45. PMID 14711313 DOI: 10.1021/Jm030236O |
0.406 |
|
2004 |
Jiang K, Delarue FL, Sebti SM. EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation Oncogene. 23: 1136-1145. PMID 14647415 DOI: 10.1038/Sj.Onc.1207236 |
0.415 |
|
2003 |
Sebti SM, Der CJ. Opinion: Searching for the elusive targets of farnesyltransferase inhibitors. Nature Reviews. Cancer. 3: 945-51. PMID 14737124 DOI: 10.1038/Nrc1234 |
0.417 |
|
2003 |
Sun J, Ohkanda J, Coppola D, Yin H, Kothare M, Busciglio B, Hamilton AD, Sebti SM. Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice. Cancer Research. 63: 8922-9. PMID 14695209 |
0.304 |
|
2003 |
Sebti SM. Blocked Pathways: FTIs Shut Down Oncogene Signals Oncologist. 8: 30-38. PMID 14671226 DOI: 10.1634/Theoncologist.8-Suppl_3-30 |
0.504 |
|
2003 |
Buckner F, Yokoyama K, Lockman J, Aikenhead K, Ohkanda J, Sadilek M, Sebti S, Van Voorhis W, Hamilton A, Gelb MH. A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents. Proceedings of the National Academy of Sciences of the United States of America. 100: 15149-53. PMID 14657358 DOI: 10.1073/Pnas.2535442100 |
0.312 |
|
2003 |
Santucci R, Mackley PA, Sebti S, Alsina M. Farnesyltransferase Inhibitors and Their Role in the Treatment of Multiple Myeloma Cancer Control. 10: 384-387. PMID 14581893 DOI: 10.1177/107327480301000505 |
0.357 |
|
2003 |
Zhang Z, Wang Y, Lantry LE, Kastens E, Liu G, Hamilton AD, Sebti SM, Lubet RA, You M. Farnesyltransferase inhibitors are potent lung cancer chemopreventive agents in A/J mice with a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf. Oncogene. 22: 6257-65. PMID 13679864 DOI: 10.1038/Sj.Onc.1206630 |
0.344 |
|
2003 |
Forsberg M, Blomgran R, Lerm M, Särndahl E, Sebti SM, Hamilton A, Stendahl O, Zheng L. Differential effects of invasion by and phagocytosis of Salmonella typhimurium on apoptosis in human macrophages: Potential role of Rho-GTPases and Akt Journal of Leukocyte Biology. 74: 620-629. PMID 12960245 DOI: 10.1189/Jlb.1202586 |
0.418 |
|
2003 |
Kurzrock R, Kantarjian HM, Cortes JE, Singhania N, Thomas DA, Wilson EF, Wright JJ, Freireich EJ, Talpaz M, Sebti SM. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood. 102: 4527-34. PMID 12947010 DOI: 10.1182/Blood-2002-11-3359 |
0.337 |
|
2003 |
Peng Y, Li C, Chen L, Sebti S, Chen J. Rescue of mutant p53 transcription function by ellipticine. Oncogene. 22: 4478-87. PMID 12881704 DOI: 10.1038/Sj.Onc.1206777 |
0.354 |
|
2003 |
Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Research. 63: 1270-9. PMID 12649187 |
0.361 |
|
2003 |
Bolick SC, Landowski TH, Boulware D, Oshiro MM, Ohkanda J, Hamilton AD, Sebti SM, Dalton WS. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells. Leukemia. 17: 451-7. PMID 12592346 DOI: 10.1038/Sj.Leu.2402832 |
0.45 |
|
2003 |
Doisneau-Sixou SF, Cestac P, Chouini S, Carroll JS, Hamilton AD, Sebti SM, Poirot M, Balaguer P, Faye JC, Sutherland RL, Favre G. Contrasting effects of prenyltransferase inhibitors on estrogen-dependent cell cycle progression and estrogen receptor-mediated transcriptional activity in MCF-7 cells. Endocrinology. 144: 989-98. PMID 12586776 DOI: 10.1210/En.2002-220726 |
0.319 |
|
2003 |
Mazzocca A, Giusti S, Hamilton AD, Sebti SM, Pantaleo P, Carloni V. Growth inhibition by the farnesyltransferase inhibitor FTI-277 involves Bcl-2 expression and defective association with Raf-1 in liver cancer cell lines. Molecular Pharmacology. 63: 159-66. PMID 12488548 DOI: 10.1124/Mol.63.1.159 |
0.479 |
|
2002 |
Allal C, Pradines A, Hamilton AD, Sebti SM, Favre G. Farnesylated RhoB prevents cell cycle arrest and actin cytoskeleton disruption caused by the geranylgeranyltransferase I inhibitor GGTI-298. Cell Cycle (Georgetown, Tex.). 1: 430-7. PMID 12548020 DOI: 10.4161/Cc.1.6.272 |
0.349 |
|
2002 |
Jackson RJ, Adnane J, Coppola D, Cantor A, Sebti SM, Pledger WJ. Loss of the cell cycle inhibitors p21(Cip1) and p27(Kip1) enhances tumorigenesis in knockout mouse models. Oncogene. 21: 8486-97. PMID 12466968 DOI: 10.1038/Sj.Onc.1205946 |
0.383 |
|
2002 |
Crespo NC, Delarue F, Ohkanda J, Carrico D, Hamilton AD, Sebti SM. The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status. Cell Death and Differentiation. 9: 702-9. PMID 12058275 DOI: 10.1038/Sj.Cdd.4401023 |
0.74 |
|
2002 |
Ohkanda J, Knowles DB, Blaskovich MA, Sebti SM, Hamilton AD. Inhibitors of protein farnesyltransferase as novel anticancer agents. Current Topics in Medicinal Chemistry. 2: 303-23. PMID 11944822 DOI: 10.2174/1568026023394281 |
0.457 |
|
2002 |
Walters CE, Pryce G, Hankey DJ, Sebti SM, Hamilton AD, Baker D, Greenwood J, Adamson P. Inhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system and attenuates clinical signs of disease in an animal model of multiple sclerosis. Journal of Immunology (Baltimore, Md. : 1950). 168: 4087-94. PMID 11937568 DOI: 10.4049/Jimmunol.168.8.4087 |
0.354 |
|
2002 |
Arteaga CL, Khuri F, Krystal G, Sebti S. Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer. Seminars in Oncology. 29: 15-26. PMID 11894010 DOI: 10.1053/Sonc.2002.31524 |
0.303 |
|
2002 |
Li X, Liu L, Tupper JC, Bannerman DD, Winn RK, Sebti SM, Hamilton AD, Harlan JM. Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. The Journal of Biological Chemistry. 277: 15309-16. PMID 11839765 DOI: 10.1074/Jbc.M201253200 |
0.443 |
|
2002 |
Ohkanda J, Lockman JW, Kothare MA, Qian Y, Blaskovich MA, Sebti SM, Hamilton AD. Design and synthesis of potent nonpeptidic farnesyltransferase inhibitors based on a terphenyl scaffold. Journal of Medicinal Chemistry. 45: 177-88. PMID 11754590 DOI: 10.1021/Jm0103099 |
0.351 |
|
2002 |
Adnane J, Seijo E, Chen Z, Bizouarn F, Leal M, Sebti SM, Muñoz-Antonia T. Rhob, not RhoA, represses the transcription of the transforming growth factor β type II receptor by a mechanism involving activator protein 1 Journal of Biological Chemistry. 277: 8500-8507. PMID 11741970 DOI: 10.1074/Jbc.M104367200 |
0.359 |
|
2001 |
Kucich U, Rosenbloom JC, Herrick DJ, Abrams WR, Hamilton AD, Sebti SM, Rosenbloom J. Signaling events required for transforming growth factor-beta stimulation of connective tissue growth factor expression by cultured human lung fibroblasts. Archives of Biochemistry and Biophysics. 395: 103-12. PMID 11673871 DOI: 10.1006/Abbi.2001.2571 |
0.335 |
|
2001 |
Delarue FL, Taylor BS, Sebti SM. Ras and RhoA suppress whereas RhoB enhances cytokine-induced transcription of nitric oxide synthase-2 in human normal liver AKN-1 cells and lung cancer A-549 cells Oncogene. 20: 6531-6537. PMID 11641777 DOI: 10.1038/Sj.Onc.1204801 |
0.405 |
|
2001 |
Turkson J, Ryan D, Kim JS, Zhang Y, Chen Z, Haura E, Laudano A, Sebti S, Hamilton AD, Jove R. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. The Journal of Biological Chemistry. 276: 45443-55. PMID 11579100 DOI: 10.1074/Jbc.M107527200 |
0.354 |
|
2001 |
Finder JD, Petrus JL, Hamilton A, Villavicencio RT, Pitt BR, Sebti SM. Signal transduction pathways of IL-1beta-mediated iNOS in pulmonary vascular smooth muscle cells. American Journal of Physiology. Lung Cellular and Molecular Physiology. 281: L816-23. PMID 11557585 DOI: 10.1152/Ajplung.2001.281.4.L816 |
0.324 |
|
2001 |
Teng S, Sun J, Irby R, Hamilton AD, Sebti S, Yeatman TJ. v-Src transformation is mediated through farnesylated proteins. The Journal of Surgical Research. 99: 343-6. PMID 11469908 DOI: 10.1006/Jsre.2001.6184 |
0.402 |
|
2001 |
Ohkanda J, Lockman JW, Yokoyama K, Gelb MH, Croft SL, Kendrick H, Harrell MI, Feagin JE, Blaskovich MA, Sebti SM, Hamilton AD. Peptidomimetic inhibitors of protein farnesyltransferase show potent antimalarial activity. Bioorganic & Medicinal Chemistry Letters. 11: 761-4. PMID 11277514 DOI: 10.1016/S0960-894X(01)00055-5 |
0.333 |
|
2001 |
Sun J, Nam S, Lee CS, Li B, Coppola D, Hamilton AD, Dou QP, Sebti SM. CEP1612, a dipeptidyl proteasome inhibitor, induces p21WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice. Cancer Research. 61: 1280-4. PMID 11245420 |
0.37 |
|
2001 |
Crespo NC, Ohkanda J, Yen TJ, Hamilton AD, Sebti SM. The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. The Journal of Biological Chemistry. 276: 16161-7. PMID 11154688 DOI: 10.1074/jbc.M006213200 |
0.722 |
|
2000 |
Sebti SM, Hamilton AD. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene. 19: 6584-93. PMID 11426643 DOI: 10.1038/Sj.Onc.1204146 |
0.401 |
|
2000 |
Sebti SM, Hamilton AD. Design of growth factor antagonists with antiangiogenic and antitumor properties. Oncogene. 19: 6566-73. PMID 11426641 DOI: 10.1038/Sj.Onc.1204121 |
0.391 |
|
2000 |
Adnane J, Bizouarn FA, Chen Z, Ohkanda J, Hamilton AD, Munoz-Antonia T, Sebti SM. Inhibition of farnesyltransferase increases TGFbeta type II receptor expression and enhances the responsiveness of human cancer cells to TGFbeta. Oncogene. 19: 5525-33. PMID 11114730 DOI: 10.1038/Sj.Onc.1203920 |
0.455 |
|
2000 |
Sebti SM, Hamilton AD. Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues. Expert Opinion On Investigational Drugs. 9: 2767-82. PMID 11093352 DOI: 10.1517/13543784.9.12.2767 |
0.412 |
|
2000 |
Dey A, She H, Kim L, Boruch A, Guris DL, Carlberg K, Sebti SM, Woodley DT, Imamoto A, Li W. Colony-stimulating factor-1 receptor utilizes multiple signaling pathways to induce cyclin D2 expression Molecular Biology of the Cell. 11: 3835-3848. PMID 11071910 DOI: 10.1091/Mbc.11.11.3835 |
0.346 |
|
2000 |
Sebti SM, Hamilton AD. Inhibition of Rho GTPases using protein geranylgeranyltransferase I inhibitors. Methods in Enzymology. 325: 381-8. PMID 11036620 DOI: 10.1016/S0076-6879(00)25459-1 |
0.417 |
|
2000 |
Wei S, Gilvary DL, Corliss BC, Sebti S, Sun J, Straus DB, Leibson PJ, Trapani JA, Hamilton AD, Weber MJ, Djeu JY. Direct tumor lysis by NK cells uses a Ras-independent mitogen-activated protein kinase signal pathway. Journal of Immunology (Baltimore, Md. : 1950). 165: 3811-9. PMID 11034387 DOI: 10.4049/Jimmunol.165.7.3811 |
0.426 |
|
2000 |
Blaskovich MA, Lin Q, Delarue FL, Sun J, Park HS, Coppola D, Hamilton AD, Sebti SM. Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice. Nature Biotechnology. 18: 1065-70. PMID 11017044 DOI: 10.1038/80257 |
0.309 |
|
2000 |
Coxon FP, Helfrich MH, Hof RV, Sebti S, Ralston SH, Hamilton A, Rogers MJ. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. Journal of Bone and Mineral Research. 15: 1467-1476. PMID 10934645 DOI: 10.1359/Jbmr.2000.15.8.1467 |
0.321 |
|
2000 |
Cohen-Jonathan E, Muschel RJ, Gillies McKenna W, Evans SM, Cerniglia G, Mick R, Kusewitt D, Sebti SM, Hamilton AD, Oliff A, Kohl N, Gibbs JB, Bernhard EJ. Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS. Radiation Research. 154: 125-32. PMID 10931682 DOI: 10.1667/0033-7587(2000)154[0125:Fiptae]2.0.Co;2 |
0.414 |
|
2000 |
Allal C, Favre G, Couderc B, Salicio S, Sixou S, Hamilton AD, Sebti SM, Lajoie-Mazenc I, Pradines A. RhoA prenylation is required for promotion of cell growth and transformation and cytoskeleton organization but not for induction of serum response element transcription. The Journal of Biological Chemistry. 275: 31001-8. PMID 10896672 DOI: 10.1074/Jbc.M005264200 |
0.399 |
|
2000 |
Chen Z, Sun J, Pradines A, Favre G, Adnane J, Sebti SM. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice Journal of Biological Chemistry. 275: 17974-17978. PMID 10770919 DOI: 10.1074/jbc.C000145200 |
0.328 |
|
2000 |
Kucich U, Rosenbloom JC, Shen G, Abrams WR, Hamilton AD, Sebti SM, Rosenbloom J. TGF-beta1 stimulation of fibronectin transcription in cultured human lung fibroblasts requires active geranylgeranyl transferase I, phosphatidylcholine-specific phospholipase C, protein kinase C-delta, and p38, but not erk1/erk2. Archives of Biochemistry and Biophysics. 374: 313-24. PMID 10666313 DOI: 10.1006/Abbi.1999.1625 |
0.349 |
|
2000 |
Boota A, Johnson B, Lee KL, Blaskovich MA, Liu SX, Kagan VE, Hamilton A, Pitt B, Sebti SM, Davies P. Prenyltransferase inhibitors block superoxide production by pulmonary vascular smooth muscle American Journal of Physiology - Lung Cellular and Molecular Physiology. 278. PMID 10666117 DOI: 10.1152/Ajplung.2000.278.2.L329 |
0.318 |
|
2000 |
Carloni V, Pinzani M, Giusti S, Romanelli RG, Parola M, Bellomo G, Failli P, Hamilton AD, Sebti SM, Laffi G, Gentilini P. Tyrosine phosphorylation of focal adhesion kinase by PDGF is dependent on ras in human hepatic stellate cells. Hepatology (Baltimore, Md.). 31: 131-40. PMID 10613738 DOI: 10.1002/Hep.510310121 |
0.434 |
|
2000 |
Lantry LE, Zhang Z, Yao R, Crist KA, Wang Y, Ohkanda J, Hamilton AD, Sebti SM, Lubet RA, You M. Effect of farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogenesis. 21: 113-6. PMID 10607742 DOI: 10.1093/Carcin/21.1.113 |
0.376 |
|
2000 |
Jiang K, Coppola D, Crespo NC, Nicosia SV, Hamilton AD, Sebti SM, Cheng JQ. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Molecular and Cellular Biology. 20: 139-48. PMID 10594016 DOI: 10.1128/Mcb.20.1.139-148.2000 |
0.779 |
|
2000 |
Kotharé MA, Ohkanda J, Lockman JW, Qian Y, Blaskovich MA, Sebti SM, Hamilton AD. Development of a Tripeptide Mimetic Strategy for the Inhibition of Protein Farnesyltransferase Tetrahedron. 56: 9833-9841. DOI: 10.1016/S0040-4020(00)00890-5 |
0.343 |
|
1999 |
Bowman T, Yu H, Sebti S, Dalton W, Jove R. Signal Transducers and Activators of Transcription: Novel Targets for Anticancer Therapeutics. Cancer Control : Journal of the Moffitt Cancer Center. 6: 427-435. PMID 10758575 DOI: 10.1177/107327489900600501 |
0.374 |
|
1999 |
Qian Y, Marugan JJ, Fossum RD, Vogt A, Sebti SM, Hamilton AD. Probing the hydrophobic pocket of farnesyltransferase: aromatic substitution of CAAX peptidomimetics leads to highly potent inhibitors. Bioorganic & Medicinal Chemistry. 7: 3011-24. PMID 10658608 DOI: 10.1016/S0968-0896(99)00252-7 |
0.424 |
|
1999 |
Liu L, Moesner P, Kovach NL, Bailey R, Hamilton AD, Sebti SM, Harlan JM. Integrin-dependent leukocyte adhesion involves geranylgeranylated protein(s). The Journal of Biological Chemistry. 274: 33334-40. PMID 10559211 DOI: 10.1074/Jbc.274.47.33334 |
0.368 |
|
1999 |
Pollack IF, Bredel M, Erff M, Hamilton AD, Sebti SM. Inhibition of Ras and related guanosine triphosphate-dependent proteins as a therapeutic strategy for blocking malignant glioma growth: II--preclinical studies in a nude mouse model. Neurosurgery. 45: 1208-14; discussion . PMID 10549939 DOI: 10.1097/00006123-199911000-00039 |
0.372 |
|
1999 |
Mazet JL, Padieu M, Osman H, Maume G, Mailliet P, Dereu N, Hamilton AD, Lavelle F, Sebti SM, Maume BF. Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-298 disrupts MAP kinase activation and G(1)-S transition in Ki-Ras-overexpressing transformed adrenocortical cells. Febs Letters. 460: 235-40. PMID 10544242 DOI: 10.1016/S0014-5793(99)01355-1 |
0.443 |
|
1999 |
Turkson J, Bowman T, Adnane J, Zhang Y, Djeu JY, Sekharam M, Frank DA, Holzman LB, Wu J, Sebti S, Jove R. Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein. Molecular and Cellular Biology. 19: 7519-7528. PMID 10523640 DOI: 10.1128/Mcb.19.11.7519 |
0.411 |
|
1999 |
Sun J, Blaskovich MA, Knowles D, Qian Y, Ohkanda J, Bailey RD, Hamilton AD, Sebti SM. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: Combination therapy with the cytotoxic agents cisplatin, taxol, and gemcitabine Cancer Research. 59: 4919-4926. PMID 10519405 |
0.316 |
|
1999 |
O'Connor SJ, Barr KJ, Wang L, Sorensen BK, Tasker AS, Sham H, Ng SC, Cohen J, Devine E, Cherian S, Saeed B, Zhang H, Lee JY, Warner R, Tahir S, ... ... Sebti SM, et al. Second-generation peptidomimetic inhibitors of protein farnesyltransferase demonstrating improved cellular potency and significant in vivo efficacy. Journal of Medicinal Chemistry. 42: 3701-10. PMID 10479301 DOI: 10.1021/Jm9901935 |
0.377 |
|
1999 |
Cohen-Jonathan E, Toulas C, Ader I, Monteil S, Allal C, Bonnet J, Hamilton AD, Sebti SM, Daly-Schveitzer N, Favre G. The farnesyltransferase inhibitor FTI-277 suppresses the 24-kDa FGF2- induced radioresistance in HeLa cells expressing wild-type RAS Radiation Research. 152: 404-411. PMID 10477917 DOI: 10.2307/3580225 |
0.41 |
|
1999 |
Vasudevan A, Qian Y, Vogt A, Blaskovich MA, Ohkanda J, Sebti SM, Hamilton AD. Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I Journal of Medicinal Chemistry. 42: 1333-1340. PMID 10212118 DOI: 10.1021/Jm9900873 |
0.373 |
|
1999 |
Sun J, Qian Y, Chen Z, Marfurt J, Hamilton AD, Sebti SM. The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin- dependent kinase inhibitors: A potential mechanism for GGTI-298 antitumor activity Journal of Biological Chemistry. 274: 6930-6934. PMID 10066746 DOI: 10.1074/Jbc.274.11.6930 |
0.464 |
|
1999 |
Cohen Jonathan-Moyal E, Muschel R, McKenna W, Hamilton A, Sebti S, Gibbs J, Oliff A, Cerniglia G, Mick R, Bernhard E. 33 In vivo radiosensitization of human tumors expressing mutant ras by farnesyltransferase inhibitors International Journal of Radiation Oncology*Biology*Physics. 45: 163-164. DOI: 10.1016/S0360-3016(99)90051-2 |
0.398 |
|
1998 |
Adnane J, Bizouarn FA, Qian Y, Hamilton AD, Sebti SM. p21(WAF1/CIP1) is upregulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a transforming growth factor β- and Sp1- responsive element: Involvement of the small GTPase RhoA Molecular and Cellular Biology. 18: 6962-6970. PMID 9819384 DOI: 10.1128/Mcb.18.12.6962 |
0.387 |
|
1998 |
Kucich U, Rosenbloom JC, Shen G, Abrams WR, Blaskovich MA, Hamilton AD, Ohkanda J, Sebti SM, Rosenbloom J. Requirement for geranylgeranyl transferase I and acyl transferase in the TGF-β-stimulated pathway leading to elastin mRNA stabilization Biochemical and Biophysical Research Communications. 252: 111-116. PMID 9813154 DOI: 10.1006/Bbrc.1998.9544 |
0.347 |
|
1998 |
Stark WW, Blaskovich MA, Johnson BA, Qian Y, Vasudevan A, Pitt B, Hamilton AD, Sebti SM, Davies P. Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells American Journal of Physiology - Lung Cellular and Molecular Physiology. 275. PMID 9688935 DOI: 10.1152/Ajplung.1998.275.1.L55 |
0.429 |
|
1998 |
Bredel M, Pollack IF, Freund JM, Hamilton AD, Sebti SM. Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growth Neurosurgery. 43: 124-132. PMID 9657198 DOI: 10.1097/00006123-199807000-00081 |
0.461 |
|
1998 |
Qian Y, Vogt A, Vasudevan A, Sebti SM, Hamilton AD. Selective inhibition of type-I geranylgeranyltransferase in vitro and in whole cells by CAAL peptidomimetics Bioorganic and Medicinal Chemistry. 6: 293-299. PMID 9568283 DOI: 10.1016/S0968-0896(97)10040-2 |
0.306 |
|
1998 |
Sun J, Qian Y, Hamilton AD, Sebti SM. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in node mouse xenografts Oncogene. 16: 1467-1473. PMID 9525745 DOI: 10.1038/Sj.Onc.1201656 |
0.435 |
|
1998 |
Sebti SM, Hamilton AD. New approaches to anticancer drug design based on the inhibition of farnesyltransferase Drug Discovery Today. 3: 26-33. DOI: 10.1016/S1359-6446(97)01122-7 |
0.42 |
|
1998 |
McKenna WG, Wu JM, Hamilton AD, Sebti SM, Muschel RJ, Bernhard EJ. Prenyltransferase inhibitors as radiosensitizing agents for tumor cells with activated ras International Journal of Radiation Oncology*Biology*Physics. 42: 190. DOI: 10.1016/S0360-3016(98)80233-2 |
0.413 |
|
1997 |
Sebti SM, Hamilton AD. Anticancer activity of farnesyltransferase and geranylgeranyltransferase I inhibitors: prospects for drug development. Expert Opinion On Investigational Drugs. 6: 1711-4. PMID 15989575 DOI: 10.1517/13543784.6.11.1711 |
0.42 |
|
1997 |
Vogt A, Sun J, Qian Y, Hamilton AD, Sebti SM. The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SD11) in a p53-independent manner Journal of Biological Chemistry. 272: 27224-27229. PMID 9341167 DOI: 10.1074/Jbc.272.43.27224 |
0.409 |
|
1997 |
Sebti SM, Hamilton AD. Inhibition of Ras prenylation: A novel approach to cancer chemotherapy Pharmacology and Therapeutics. 74: 103-114. PMID 9336018 DOI: 10.1016/S0163-7258(97)00014-4 |
0.337 |
|
1997 |
Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines Oncogene. 15: 1283-1288. PMID 9315095 DOI: 10.1038/Sj.Onc.1201296 |
0.302 |
|
1997 |
Lerner EC, Hamilton AD, Sebti SM. Inhibition of Ras prenylation: A signaling target for novel anti-cancer drug design Anti-Cancer Drug Design. 12: 229-238. PMID 9199657 |
0.324 |
|
1997 |
Qian Y, Sebti SM, Hamilton AD. Farnesyltransferase as a target for anticancer drug design Biopolymers. 43: 25-41. PMID 9174410 DOI: 10.1002/(Sici)1097-0282(1997)43:1<25::Aid-Bip4>3.0.Co;2-2 |
0.342 |
|
1997 |
Clark GJ, Kinch MS, Rogers-Graham K, Sebti SM, Hamilton AD, Der CJ. The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation Journal of Biological Chemistry. 272: 10608-10615. PMID 9099708 DOI: 10.1074/Jbc.272.16.10608 |
0.363 |
|
1997 |
McGuire TF, Sebti SM. Geranylgeraniol potentiates lovastatin inhibition of oncogenic H-Ras processing and signaling while preventing cytotoxicity Oncogene. 14: 305-312. PMID 9018116 DOI: 10.1038/Sj.Onc.1200819 |
0.426 |
|
1997 |
Pollack IF, Bredel M, Freund JM, Sebti SM. Inhibition of malignant glioma growth by blocking p21RAS processing Clinical Neurology and Neurosurgery. 99. DOI: 10.1016/S0303-8467(97)82340-2 |
0.351 |
|
1996 |
McGuire TF, Qian Y, Vogt A, Hamilton AD, Sebti SM. Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation Journal of Biological Chemistry. 271: 27402-27407. PMID 8910319 DOI: 10.1074/Jbc.271.44.27402 |
0.391 |
|
1996 |
Pei Z, Sebti SM. Cys 102 and His 398 are required for bleomycin-inactivating activity but not for hexamer formation of yeast bleomycin hydrolase Biochemistry. 35: 10751-10756. PMID 8718865 DOI: 10.1021/Bi9605447 |
0.303 |
|
1995 |
Vogt A, Qian Y, Blaskovich MA, Fossum RD, Hamilton AD, Sebti SM. A non-peptide mimetic of Ras-CAAX: Selective inhibition of farnesyltransferase and Ras processing Journal of Biological Chemistry. 270: 660-664. PMID 7822292 DOI: 10.1074/Jbc.270.2.660 |
0.362 |
|
1995 |
Sun J, Sebti SM, Qian Y, Hamilton AD. Ras CAAX Peptidomimetic FTI 276 Selectively Blocks Tumor Growth in Nude Mice of a Human Lung Carcinoma with K-Ras Mutation and p53 Deletion Cancer Research. 55: 4243-4247. PMID 7671229 |
0.338 |
|
1995 |
Lernert EC, Qian Y, Hamilton AD, Sebti SM. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor Journal of Biological Chemistry. 270: 26770-26773. PMID 7592913 DOI: 10.1074/Jbc.270.45.26770 |
0.391 |
|
1995 |
Sebti SM. Burkitt lymphoma daudi cells contain two distinct farnesyltransferases with different divalent cation requirements Biochemistry. 34: 12398-12403. PMID 7547984 DOI: 10.1021/Bi00038A037 |
0.318 |
|
1995 |
Kauffmann RC, Qian Y, Vogt A, Sebti SM, Hamilton AD, Carthew RW. Activated Drosophila Ras1 is selectively suppressed by isoprenyl transferase inhibitors. Proceedings of the National Academy of Sciences of the United States of America. 92: 10919-23. PMID 7479910 DOI: 10.1073/Pnas.92.24.10919 |
0.334 |
|
1985 |
Sebti SM, Moynihan CG, Anderson JN, Baird WM. Benzo[a]pyrene-dna adduct formation in target and activator cells in a wistar rat embryo cell-mediated v79 cell mutation assay Carcinogenesis. 6: 983-988. PMID 4017178 DOI: 10.1093/Carcin/6.7.983 |
0.303 |
|
Low-probability matches (unlikely to be authored by this person) |
2003 |
Ohkanda J, Blaskovich MA, Sebti SM, Hamilton AD. The development of protein farnesyltransferase inhibitors as signaling-based anticancer agents. Progress in Cell Cycle Research. 5: 211-7. PMID 14593715 |
0.298 |
|
2011 |
Hu Y, Li X, Sebti SM, Chen J, Cai J. Design and synthesis of AApeptides: a new class of peptide mimics. Bioorganic & Medicinal Chemistry Letters. 21: 1469-71. PMID 21292484 DOI: 10.1016/J.Bmcl.2011.01.005 |
0.298 |
|
2019 |
Kazi A, Xiang S, Yang H, Delitto D, Trevino J, Jiang RH, Ayaz M, Lawrence H, Kennedy P, Sebti SM. Abstract 1310: Abrogation of KRas-addicted tumors by GSK3 suppression-mediated upregulation of β-catenin and c-myc Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-1310 |
0.296 |
|
2023 |
Dailey JM, Kee SA, Tharakan A, Kazi A, Burchett JR, Kolawole EM, Boyd Ballance W, Kotha A, Le QT, Schwartz LB, Straus DB, Martin RK, Sebti SM, Ryan JJ. Inhibiting Isoprenylation Suppresses FcεRI-Mediated Mast Cell Function and Allergic Inflammation. Journal of Immunology (Baltimore, Md. : 1950). PMID 37449905 DOI: 10.4049/jimmunol.2200862 |
0.295 |
|
2013 |
Lawrence NJ, Pireddu R, Ge Y, Urlam MK, Zhang X, Sun Y, Lawrence HR, Guida WC, Sebti S. Abstract 2467: Development of new N-Arylbenzamides as STAT3 dimerization inhibitors. Cancer Research. 73: 2467-2467. DOI: 10.1158/1538-7445.Am2013-2467 |
0.293 |
|
2019 |
Francois RA, Zhang A, Husain K, Wang C, Hutchinson S, Kongnyuy M, Batra SK, Coppola D, Sebti SM, Malafa MP. Vitamin E δ-tocotrienol sensitizes human pancreatic cancer cells to TRAIL-induced apoptosis through proteasome-mediated down-regulation of c-FLIP. Cancer Cell International. 19: 189. PMID 31367187 DOI: 10.1186/S12935-019-0876-0 |
0.293 |
|
2007 |
Gunning PT, Katt WP, Glenn M, Siddiquee K, Kim JS, Jove R, Sebti SM, Turkson J, Hamilton AD. Corrigendum to "Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: Structural recognition of STAT SH2 domains" [Bioorg. Med. Chem. Lett. 17 (2007) 1875-1878] (DOI:10.1016/j.bmcl.2007.01.077) Bioorganic and Medicinal Chemistry Letters. 17: 2949. DOI: 10.1016/J.Bmcl.2007.03.063 |
0.293 |
|
2009 |
Sparano JA, Moulder S, Kazi A, Coppola D, Negassa A, Vahdat L, Li T, Pellegrino C, Fineberg S, Munster P, Malafa M, Lee D, Hoschander S, Hopkins U, Hershman D, ... ... Sebti SM, et al. Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 2942-8. PMID 19351752 DOI: 10.1158/1078-0432.Ccr-08-2658 |
0.292 |
|
2009 |
Wei J, Kitada S, Rega MF, Emdadi A, Yuan H, Cellitti J, Stebbins JL, Zhai D, Sun J, Yang L, Dahl R, Zhang Z, Wu B, Wang S, Reed TA, ... ... Sebti S, et al. Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins. Molecular Cancer Therapeutics. 8: 904-13. PMID 19372563 DOI: 10.1158/1535-7163.Mct-08-1050 |
0.292 |
|
1998 |
Bernhard EJ, McKenna WG, Hamilton AD, Sebti SM, Qian Y, Wu JM, Muschel RJ. Inhibiting ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes Cancer Research. 58: 1754-1761. PMID 9563495 |
0.291 |
|
1996 |
Stark W, Sebti SM, Davies P. Constitutlvely active ras reduces the incidence of apoptosis in nffl 3t3 cells Faseb Journal. 10. |
0.291 |
|
2004 |
Sebti SM, Adjei AA. Farnesyltransferase inhibitors. Seminars in Oncology. 31: 28-39. PMID 14981578 |
0.291 |
|
1993 |
McGuire TF, Corey SJ, Sebti SM. Lovastatin inhibits platelet-derived growth factor (PDGF) stimulation of phosphatidylinositol 3-kinase activity as well as association of p85 subunit to tyrosine-phosphorylated PDGF receptor Journal of Biological Chemistry. 268: 22227-22230. PMID 7693661 |
0.291 |
|
2018 |
Kazi A, Xiang S, Yang H, Delitto D, Trevino J, Jiang RHY, Ayaz M, Lawrence HR, Kennedy P, Sebti SM. GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors. Nature Communications. 9: 5154. PMID 30514931 DOI: 10.1038/s41467-018-07644-6 |
0.29 |
|
2011 |
Husain K, Coppola D, Centeno B, Helm R, Dung-Tsa C, Sebti S, Malafa M. Abstract 1667: In vitro and in vivo validation of CSE1L/hCAS as a potential molecular target in pancreatic cancer Cancer Research. 71: 1667-1667. DOI: 10.1158/1538-7445.Am2011-1667 |
0.288 |
|
2003 |
Zhu K, Hamilton AD, Sebti SM. Farnesyltransferase inhibitors as anticancer agents: current status. Current Opinion in Investigational Drugs (London, England : 2000). 4: 1428-35. PMID 14763128 |
0.287 |
|
1991 |
Sebti SM, Tkalcevic GT, Jani JP. Lovastatin, a cholesterol biosynthesis inhibitor, inhibits the growth of human H-ras oncogene transformed cells in nude mice Cancer Communications. 3: 141-147. PMID 2043425 |
0.287 |
|
2005 |
Yin H, Lee GI, Sedey KA, Rodriguez JM, Wang HG, Sebti SM, Hamilton AD. Terephthalamide derivatives as mimetics of helical peptides: disruption of the Bcl-x(L)/Bak interaction. Journal of the American Chemical Society. 127: 5463-8. PMID 15826183 DOI: 10.1021/Ja0446404 |
0.287 |
|
2005 |
Cloughesy TF, Kuhn J, Robins HI, Abrey L, Wen P, Fink K, Lieberman FS, Mehta M, Chang S, Yung A, DeAngelis L, Schiff D, Junck L, Groves M, Paquette S, ... ... Sebti SM, et al. Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 6647-56. PMID 16170172 DOI: 10.1200/Jco.2005.10.068 |
0.286 |
|
2003 |
Bordier BB, Ohkanda J, Liu P, Lee SY, Salazar FH, Marion PL, Ohashi K, Meuse L, Kay MA, Casey JL, Sebti SM, Hamilton AD, Glenn JS. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. The Journal of Clinical Investigation. 112: 407-14. PMID 12897208 DOI: 10.1172/Jci17704 |
0.286 |
|
2011 |
Springett GM, Neuger AM, Centeno BA, Hutchinson T, Jump H, Lush R, Sebti S, Malafa MP. Abstract 1299: A phase I dose-escalation study of the safety, PK, and PD of vitamin E Δ-tocotrienol administered to subjects with resectable pancreatic exocrine neoplasia Cancer Research. 71: 1299-1299. DOI: 10.1158/1538-7445.Am2011-1299 |
0.286 |
|
2008 |
Epling-Burnette PK, Sokol L, Chen X, Bai F, Zhou J, Blaskovich MA, Zou J, Painter JS, Edwards TD, Moscinski L, Yoder JA, Djeu JY, Sebti S, Loughran TP, Wei S. Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling. Blood. 112: 4694-8. PMID 18791165 DOI: 10.1182/Blood-2008-02-136382 |
0.283 |
|
2005 |
Yin H, Lee GI, Sedey KA, Kutzki O, Park HS, Orner BP, Ernst JT, Wang HG, Sebti SM, Hamilton AD. Terphenyl-Based Bak BH3 alpha-helical proteomimetics as low-molecular-weight antagonists of Bcl-xL. Journal of the American Chemical Society. 127: 10191-6. PMID 16028929 DOI: 10.1021/Ja050122X |
0.282 |
|
2019 |
Karasic TB, Chiorean EG, Sebti SM, O'Dwyer PJ. A Phase I Study of GGTI-2418 (Geranylgeranyl Transferase I Inhibitor) in Patients with Advanced Solid Tumors. Targeted Oncology. PMID 31372813 DOI: 10.1007/s11523-019-00661-5 |
0.279 |
|
2012 |
Kumar N, Crocker T, Smith T, Connors S, Pow-Sang J, Spiess PE, Egan K, Quinn G, Schell M, Sebti S, Kazi A, Chuang T, Salup R, Helal M, Zagaja G, et al. Prostate Cancer Chemoprevention Targeting Men with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar Proliferation (ASAP): Model for Trial Design and Outcome Measures. Journal of Clinical Trials. 2. PMID 24533253 DOI: 10.4172/Jctr.1000105 |
0.277 |
|
2018 |
Carbone M, Amelio I, Affar EB, Brugarolas J, Cannon-Albright LA, Cantley LC, Cavenee WK, Chen Z, Croce CM, Andrea A, Gandara D, Giorgi C, Jia W, Lan Q, Mak TW, ... ... Sebti SM, et al. Consensus report of the 8 and 9th Weinman Symposia on Gene x Environment Interaction in carcinogenesis: novel opportunities for precision medicine. Cell Death and Differentiation. PMID 30323273 DOI: 10.1038/S41418-018-0213-5 |
0.277 |
|
1995 |
Lerner EC, Qian Y, Blaskovich MA, Fossum RD, Vogt A, Sun J, Cox AD, Der CJ, Hamilton AD, Sebti SM. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes Journal of Biological Chemistry. 270: 26802-26806. PMID 7592920 DOI: 10.1074/Jbc.270.45.26802 |
0.276 |
|
2016 |
Li H, Kuwajima T, Oakley D, Nikulina E, Hou J, Yang WS, Lowry ER, Lamas NJ, Amoroso MW, Croft GF, Hosur R, Wichterle H, Sebti S, Filbin MT, Stockwell B, et al. Protein Prenylation Constitutes an Endogenous Brake on Axonal Growth. Cell Reports. PMID 27373155 DOI: 10.1016/J.Celrep.2016.06.013 |
0.276 |
|
2007 |
Epifano F, Curini M, Genovese S, Blaskovich M, Hamilton A, Sebti SM. Corrigendum to "Prenyloxyphenylpropanoids as novel lead compounds for the selective inhibition of geranylgeranyl transferase I" [Bioorg. Med. Chem. Lett. 17 (2007) 2639-2642] (DOI:10.1016/j.bmcl.2007.01.097) Bioorganic and Medicinal Chemistry Letters. 17: 5492. DOI: 10.1016/J.Bmcl.2007.07.042 |
0.275 |
|
2013 |
Zhang X, Sun Y, Pireddu R, Yang H, Urlam MK, Lawrence HR, Guida WC, Lawrence NJ, Sebti SM. A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation Cancer Research. 73: 1922-1933. PMID 23322008 DOI: 10.1158/0008-5472.Can-12-3175 |
0.273 |
|
1993 |
Nigam M, Seong CM, Qian Y, Hamilton AD, Sebti SM. Potent inhibition of human tumor p21ras farnesyltransferase by A1A2-lacking p21ras CA1A2X peptidomimetics. The Journal of Biological Chemistry. 268: 20695-8. PMID 8407887 |
0.273 |
|
2011 |
Berndt N, Hamilton AD, Sebti SM. Targeting protein prenylation for cancer therapy. Nature Reviews. Cancer. 11: 775-91. PMID 22020205 DOI: 10.1038/Nrc3151 |
0.272 |
|
2012 |
Bai F, Villagra AV, Zou J, Painter JS, Connolly K, Blaskovich MA, Sokol L, Sebti S, Djeu JY, Loughran TP, Wei S, Sotomayor E, Epling-Burnette P. Tipifarnib-mediated suppression of T-bet-dependent signaling pathways. Cancer Immunology, Immunotherapy : Cii. 61: 523-33. PMID 21983879 DOI: 10.1007/S00262-011-1109-0 |
0.269 |
|
2005 |
Carrico D, Blaskovich MA, Bucher CJ, Sebti SM, Hamilton AD. Design, synthesis, and evaluation of potent and selective benzoyleneurea-based inhibitors of protein geranylgeranyltransferase-I. Bioorganic & Medicinal Chemistry. 13: 677-88. PMID 15653335 DOI: 10.1016/J.Bmc.2004.10.053 |
0.268 |
|
2006 |
Ohkanda J, Strickland CL, Blaskovich MA, Carrico D, Lockman JW, Vogt A, Bucher CJ, Sun J, Qian Y, Knowles D, Pusateri EE, Sebti SM, Hamilton AD. Structure-based design of imidazole-containing peptidomimetic inhibitors of protein farnesyltransferase. Organic & Biomolecular Chemistry. 4: 482-92. PMID 16446806 DOI: 10.1039/B508184J |
0.267 |
|
2009 |
Husain K, Francois RA, Hutchinson SZ, Neuger AM, Lush R, Coppola D, Sebti S, Malafa MP. Vitamin E δ-Tocotrienol Levels in Tumor and Pancreatic Tissue of Mice after Oral Administration Pharmacology. 83: 157-163. PMID 19142032 DOI: 10.1159/000190792 |
0.267 |
|
2000 |
Rosenbloom J, Saitta B, Gaidarova S, Sandorfi N, Rosenbloom JC, Abrams WR, Hamilton AD, Sebti SM, Kucich U, Jimenez SA. Inhibition of type I collagen gene expression in normal and systemic sclerosis fibroblasts by a specific inhibitor of geranylgeranyl transferase I. Arthritis and Rheumatism. 43: 1624-32. PMID 10902768 DOI: 10.1002/1529-0131(200007)43:7<1624::Aid-Anr28>3.0.Co;2-E |
0.266 |
|
1996 |
Bernhard EJ, Kao G, Cox AD, Sebti SM, Hamilton AD, Muschel RJ, McKenna WG. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts Cancer Research. 56: 1727-1730. PMID 8620483 |
0.264 |
|
1986 |
Baird WM, Sebti SM, Reinsvold LA. Metabolic activation of benzo(a)pyrene in SENCAR and BALB/c mouse embryo cell cultures Environmental Health Perspectives. 45-52. PMID 3780631 DOI: 10.1289/Ehp.866845 |
0.261 |
|
1987 |
Sebti SM, Lazo JS. Separation of the protective enzyme bleomycin hydrolase from rabbit pulmonary aminopeptidases Biochemistry. 26: 432-437. PMID 3103681 DOI: 10.1021/Bi00376A014 |
0.26 |
|
2000 |
Adnane J, Jackson RJ, Nicosia SV, Cantor AB, Pledger WJ, Sebti SM. Loss of p21WAF1/CIP1 accelerates Ras oncogenesis in a transgenic/knockout mammary cancer model. Oncogene. 19: 5338-47. PMID 11103935 DOI: 10.1038/Sj.Onc.1203956 |
0.256 |
|
1989 |
Sebti SM, Deleon JC, Ma LT, Hecht SM, Lazo JS. Substrate specificity of bleomycin hydrolase Biochemical Pharmacology. 38: 141-147. PMID 2462878 DOI: 10.1016/0006-2952(89)90160-3 |
0.256 |
|
2005 |
Yin H, Lee GI, Park HS, Payne GA, Rodriguez JM, Sebti SM, Hamilton AD. Terphenyl-based helical mimetics that disrupt the p53/HDM2 interaction. Angewandte Chemie (International Ed. in English). 44: 2704-7. PMID 15765497 DOI: 10.1002/Anie.200462316 |
0.255 |
|
2010 |
Solhy A, Sebti S, Tahir R, Sebti J, Ould Abba M, Bousmina M, Vaudreuil S, Zahouily M. Remarkable catalytic activity of sodium-modified-hydroxyapatite in the synthesis of α-hydroxyphosphonates Current Organic Chemistry. 14: 1517-1522. DOI: 10.2174/138527210791616821 |
0.255 |
|
2003 |
Saber A, Smahi A, Solhy A, Nazih R, Elaabar B, Maizi M, Sebti S. Heterogeneous catalysis of Friedel-Crafts alkylation by the fluorapatite alone and doped with metal halides Journal of Molecular Catalysis a-Chemical. 202: 229-237. DOI: 10.1016/S1381-1169(03)00186-9 |
0.251 |
|
2015 |
Kumar NB, Pow-Sang J, Egan KM, Spiess PA, Dickinson S, Salup R, Helal M, McLarty J, Williams CR, Schreiber F, Sebti S, Kazi A, Kang L, Quinn G, Smith T, et al. Abstract PR06: Effect of polyphenon E on progression to prostate cancer after diagnosis of high grade prostatic intraepithelial neoplasia Cancer Prevention Research. 8. DOI: 10.1158/1940-6215.Prev-14-Pr06 |
0.25 |
|
2015 |
Kumar NB, Pow-Sang J, Egan KM, Spiess PE, Dickinson S, Salup R, Helal M, McLarty JW, Williams CR, Schreiber F, Parnes HL, Sebti S, Kazi A, Kang L, Quinn GP, et al. Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention. Cancer Prevention Research (Philadelphia, Pa.). PMID 25873370 DOI: 10.1158/1940-6207.Capr-14-0324 |
0.25 |
|
1987 |
Sebti SM. Purification, characterization, and amino acid composition of rabbit pulmonary bleomycin hydrolase Biochemistry. 26: 4213-4219. PMID 3117099 DOI: 10.1021/Bi00388A006 |
0.249 |
|
2002 |
Adnane J, Muro-Cacho C, Mathews L, Sebti SM, Muñoz-Antonia T. Suppression of rho B expression in invasive carcinoma from head and neck cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 2225-32. PMID 12114424 |
0.245 |
|
2013 |
Ramananarivo HR, Solhy A, Sebti J, Smahi A, Zahouily M, Clark J, Sebti S. An eco-friendly paradigm for the synthesis of α-hydroxyphosphonates using sodium-modified fluorapatite under solventless conditions Acs Sustainable Chemistry and Engineering. 1: 403-409. DOI: 10.1021/Sc3001417 |
0.243 |
|
2007 |
Zahouily M, Elmakssoudi A, Mezdar A, Rayadh A, Sebti S. Natural phosphate and potassium fluoride doped natural phosphate catalysed simple one-pot synthesis of α-amino phosphonates under solvent-free conditions at room temperature Catalysis Communications. 8: 225-230. DOI: 10.1016/J.Catcom.2006.06.017 |
0.242 |
|
2015 |
Springett GM, Husain K, Neuger A, Centeno B, Chen DT, Hutchinson TZ, Lush RM, Sebti S, Malafa MP. A Phase I Safety, Pharmacokinetic, and Pharmacodynamic Presurgical Trial of Vitamin E δ-tocotrienol in Patients with Pancreatic Ductal Neoplasia. Ebiomedicine. 2: 1987-95. PMID 26844278 DOI: 10.1016/J.Ebiom.2015.11.025 |
0.242 |
|
2007 |
Zahouily M, Mounir B, Cherki H, Bahlaouan B, Rayadh A, Sebti S. Natural Phosphate Modified with Lithium Nitrate: A New Efficient Catalyst for the Construction of Carbon–Carbon, Carbon–Sulfur, and Carbon–Nitrogen Bonds Phosphorus Sulfur and Silicon and the Related Elements. 182: 1203-1217. DOI: 10.1080/10426500601160397 |
0.24 |
|
2005 |
Zahouily M, Mezdar A, Rakik J, Elmakssoudi A, Rayadh A, Sebti S. A mild and efficient method for the protection of carbonyl compounds as dithioacetals, dithiolanes and dithianes catalysed by iodine supported on natural phosphate Journal of Molecular Catalysis a-Chemical. 233: 43-47. DOI: 10.1016/J.Molcata.2005.01.043 |
0.24 |
|
1994 |
Qian Y, Blaskovich MA, Saleem M, Seong CM, Wathen SP, Hamilton AD, Sebti SM. Design and structural requirements of potent peptidomimetic inhibitors of p21ras farnesyltransferase Journal of Biological Chemistry. 269: 12410-12413. PMID 8175645 |
0.24 |
|
2015 |
Kim R, Yamauchi T, Husain K, Sebti S, Malafa M. Triciribine Phosphate Monohydrate, an AKT Inhibitor, Enhances Gemcitabine Activity in Pancreatic Cancer Cells. Anticancer Research. 35: 4599-604. PMID 26254348 |
0.239 |
|
2012 |
Kumar N, Crocker T, Smith T, Pow-Sang J, Spiess PE, Egan K, Quinn G, Schell M, Sebti S, Kazi A, Chuang T, Salup R, Helal M, Zagaja G, Trabulsi E, et al. Challenges and potential solutions to meeting accrual goals in a Phase II chemoprevention trial for prostate cancer. Contemporary Clinical Trials. 33: 279-85. PMID 22101219 DOI: 10.1016/J.Cct.2011.11.004 |
0.238 |
|
2005 |
Zahouily M, Mezdar A, Elmakssoudi A, Rayadh A, Sebti S, Lazrek HB. Comparison of different Lewis acids supported on natural phosphate as new catalysts for chemoselective dithioacetalization of carbonyl compounds under solvent-free conditions Arkivoc. 2006. DOI: 10.3998/Ark.5550190.0007.203 |
0.238 |
|
2015 |
Kumar NB, Pow-Sang J, Egan K, Spiess PE, Dickinson SI, Salup R, Helal M, McLarty J, Williams CR, Schreiber FJ, Parnes H, Sebti S, Kazi A, Kang L, Quinn GP, et al. Effect of green tea catechins in prostate cancer chemoprevention. Journal of Clinical Oncology. 33: 1572-1572. DOI: 10.1200/Jco.2015.33.15_Suppl.1572 |
0.236 |
|
1996 |
Xu XQ, McGuire TF, Blaskovich MA, Sebti SM, Romero G. Lovastatin inhibits the stimulation of mitogen-activated protein kinase by insulin in HIRcB fibroblasts Archives of Biochemistry and Biophysics. 326: 233-237. PMID 8611028 DOI: 10.1006/Abbi.1996.0070 |
0.236 |
|
2005 |
Sebti SM. Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy. Cancer Cell. 7: 297-300. PMID 15837619 DOI: 10.1016/j.ccr.2005.04.005 |
0.236 |
|
1995 |
Hamilton AD, Sebti SM. Inhibitors of ras farnesyltransferase as novel antitumor agents Drug News and Perspectives. 8: 138-145. |
0.233 |
|
2011 |
Kazi A, Sun J, Doi K, Sung SS, Takahashi Y, Yin H, Rodriguez JM, Becerril J, Berndt N, Hamilton AD, Wang HG, Sebti SM. The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner. The Journal of Biological Chemistry. 286: 9382-92. PMID 21148306 DOI: 10.1074/Jbc.M110.203638 |
0.231 |
|
2005 |
Elmakssoudi A, Zahouily M, Mezdar A, Rayadh A, Sebti S. Na2CaP2O7 a new catalyst for the synthesis of α-amino phosphonates under solvent-free conditions at room temperature Comptes Rendus Chimie. 8: 1954-1959. DOI: 10.1016/J.Crci.2005.05.006 |
0.231 |
|
2019 |
Boucher JC, Li G, Kotani H, Cabral M, Morrissey D, Lee SB, Spitler K, Beatty N, Shrestha B, Yu B, Kazi A, Wang X, Sebti S, Davila ML. Mutation of the CD28 Co-Stimulatory Domain Confers Enhanced CAR T Cell Function Blood. 134: 248-248. DOI: 10.1182/Blood-2019-122954 |
0.23 |
|
2006 |
Bazi F, Badaoui HE, Tamani S, Sokori S, Solhy A, Macquarrie DJ, Sebti S. A facile synthesis of amides by selective hydration of nitriles using modified natural phosphate and hydroxyapatite as new catalysts Applied Catalysis a-General. 301: 211-214. DOI: 10.1016/J.Apcata.2005.12.003 |
0.23 |
|
2001 |
Bennazha J, Zahouily M, Sebti S, Boukhari A, Holt EM. Na2CaP2O7, a new catalyst for Knoevenagel reaction Catalysis Communications. 2: 101-104. DOI: 10.1016/S1566-7367(01)00015-2 |
0.226 |
|
2003 |
Rochdi A, Taourirte M, Redwane N, Sebti S, Engels JW, Lazrek HB. Doped natural phosphate: a new and environmentally friendly catalyst in nucleoside synthesis. Nucleosides, Nucleotides & Nucleic Acids. 22: 679-81. PMID 14565252 DOI: 10.1081/Ncn-120022699 |
0.225 |
|
2004 |
Zahouily M, Salah M, Bahlaouan B, Mounir B, Rayadh A, Sebti S. Sodium/fluorapatite as a new solid support for the synthesis of α, β-unsaturated arylsulfones Catalysis Letters. 96: 57-61. DOI: 10.1023/B:Catl.0000029529.98306.5F |
0.225 |
|
2020 |
Walton K, Fernandez MR, Sagatys EM, Reff J, Kim J, Lee MC, Kiluk J, Hui JYC, McKenna D, Hupp M, Forster C, Linden MA, Lawrence NJ, Lawrence HR, Pidala J, ... ... Sebti SM, et al. Metabolic reprogramming augments potency of human pSTAT3-inhibited iTregs to suppress alloreactivity. Jci Insight. PMID 32255769 DOI: 10.1172/Jci.Insight.136437 |
0.223 |
|
2005 |
Zahouily M, Bahlaouan W, Bahlaouan B, Rayadh A, Sebti S. Catalysis by hydroxyapatite alone and modified by sodium nitrate: a simple and efficient procedure for the construction of carbon-nitrogen bonds in heterogeneous catalysis Arkivoc. 2005. DOI: 10.3998/Ark.5550190.0006.D13 |
0.223 |
|
2006 |
Zahouily M, Bahlaouan B, Abrouki Y, Salah M, Bahlaouan O, Rayadh A, Aadil M, Sebti S. Natural Phosphate and Potassium Fluoride Doped Natural Phosphate as New Catalysts for the Vilsmeir–Haack type Reaction Journal of Chemical Research-S. 2006: 34-36. DOI: 10.3184/030823406776331043 |
0.221 |
|
2000 |
Sebti S, Nazih R, Tahir R, Salhi L, Saber A. Fluorapatite: new solid catalyst of the Knoevenagel reaction in heterogeneous media without solvent Applied Catalysis a-General. 197. DOI: 10.1016/S0926-860X(99)00492-5 |
0.221 |
|
1999 |
Lazrek HB, Rochdi A, Kabbaj Y, Taourirte M, Sebti S. Zinc Chloride Doped Natural Phosphate as 1,3-Dipolar Cycloaddition Catalyst Synthetic Communications. 29: 1057-1063. DOI: 10.1080/00397919908086072 |
0.22 |
|
2010 |
Solhy A, Tahir R, Sebti S, Skouta R, Bousmina M, Zahouily M, Larzek M. Efficient synthesis of chalcone derivatives catalyzed by re-usable hydroxyapatite Applied Catalysis a: General. 374: 189-193. DOI: 10.1016/J.Apcata.2009.12.008 |
0.219 |
|
2016 |
Kim D, Sun M, He L, Zhou QH, Chen J, Sun XM, Bepler G, Sebti SM, Cheng JQ. A small molecule inhibits Akt through direct binding to Akt and preventing Akt membrane translocation. The Journal of Biological Chemistry. 291: 22856. PMID 27825094 DOI: 10.1074/jbc.A109.094060 |
0.219 |
|
2008 |
Smahi A, Solhy A, Tahir R, Sebti S, Mayoral JA, García JI, Fraile JM, Zahouily M. Preparation of α-hydroxyphosphonates over phosphate catalysts Catalysis Communications. 9: 2503-2508. DOI: 10.1016/J.Catcom.2008.07.005 |
0.218 |
|
1996 |
Qian Y, Vogt A, Sebti SM, Hamilton AD. Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferase inhibitors Journal of Medicinal Chemistry. 39: 217-223. PMID 8568811 DOI: 10.1021/Jm950414G |
0.218 |
|
2005 |
Badaoui HE, Bazi F, Tamani S, Boulaajaj S, Zahouily M, Lazrek HB, Sebti S. Lewis Acid–Doped Natural Phosphate: New Catalysts for the One‐Pot Synthesis of 3,4‐Dihydropyrimdin‐2(1H)‐one Synthetic Communications. 35: 2561-2568. DOI: 10.1080/00397910500213963 |
0.218 |
|
1997 |
Miquel K, Pradines A, Sun J, Qian Y, Hamilton AD, Sebti SM, Favre G. GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2- M enrichment in A549 cells Cancer Research. 57: 1846-1850. PMID 9157972 |
0.218 |
|
2003 |
Zahouily M, Abrouki Y, Bahlaouan B, Rayadh A, Sebti S. Hydroxyapatite: new efficient catalyst for the Michael addition Catalysis Communications. 4: 521-524. DOI: 10.1016/J.Catcom.2003.08.001 |
0.217 |
|
2008 |
Sun J, Blaskovich MA, Jove R, Livingston SK, Coppola D, Sebti SM. Cucurbitacin Q: A selective STAT3 activation inhibitor with potent antitumor activity (Oncogene (2005) 24, (3236-3245) DOI: 10.1038/sj.onc.1208470) ) Oncogene. 27: 1344. DOI: 10.1038/sj.onc.1211028 |
0.216 |
|
2003 |
Zahouily M, Abrouki Y, Rayadh A, Sebti S, Dhimane H, David M. Fluorapatite: efficient catalyst for the Michael addition Tetrahedron Letters. 44: 2463-2465. DOI: 10.1016/S0040-4039(03)00323-X |
0.214 |
|
2023 |
Tyc KM, Kazi A, Ranjan A, Wang R, Sebti SM. Novel mutant KRAS addiction signature predicts response to the combination of ERBB and MEK inhibitors in lung and pancreatic cancers. Iscience. 26: 106082. PMID 36852277 DOI: 10.1016/j.isci.2023.106082 |
0.213 |
|
1994 |
Qian Y, Blaskovich MA, Seong CM, Vogt A, Hamilton AD, Sebti SM. Peptidomimetic inhibitors of p21ras farnesyltransferase: Hydrophobic functionalization leads to disruption of p21ras membrane association in whole cells Bioorganic and Medicinal Chemistry Letters. 4: 2579-2584. DOI: 10.1016/S0960-894X(01)80287-0 |
0.211 |
|
2005 |
Zahouily M, Elmakssoudi A, Mezdar A, Rayadh A, Sebti S. Uncatalysed preparation of α-amino phosphonates under solvent free conditions Journal of Chemical Research-S. 2005: 324-327. DOI: 10.3184/0308234054323887 |
0.211 |
|
2021 |
Walton K, Walker K, Riddle M, Koehn BH, Reff J, Sagatys EM, Linden MA, Pidala J, Kim J, Lee MC, Kiluk JV, Hui JYC, Yun SY, Xing Y, Stefanski H, ... ... Sebti SM, et al. Dual JAK2/Aurora kinase A inhibition prevents human skin graft rejection by allo-inactivation and ILC2-mediated tissue repair. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. PMID 34668635 DOI: 10.1111/ajt.16870 |
0.211 |
|
2018 |
Bazi F, Mounir B, Hamza M, Sebti S. A Mild and Efficient Method for the Synthesis of Acylals from Aromatic Aldehydes and Their Deprotections Catalyzed by Synthetic Phosphates under Solvent-Free Conditions Green and Sustainable Chemistry. 8: 334-344. DOI: 10.4236/Gsc.2018.84023 |
0.21 |
|
2005 |
Badaoui HE, Bazi F, Sokori S, Boulaajaj S, Lazrek HB, Sebti S. One-Pot Synthesis of 3,4-Dihydropyrimidin-2(1H)-ones Using ZnCl2, CuCl2, NiCl2 and CoCl2 Doped Hydroxyapatite Letters in Organic Chemistry. 2: 561-565. DOI: 10.2174/1570178054640750 |
0.21 |
|
1992 |
Jani JP, Mistry JS, Morris G, Lazo JS, Sebti SM. In vivo sensitization of human lung carcinoma to bleomycin by the cysteine proteinase inhibitor E-64. Oncology Research. 4: 59-63. PMID 1375852 |
0.21 |
|
2005 |
Lazrek HB, Taourirte M, Rochdi A, Redwane N, Ouzebla D, Baddi L, Sebti S, Vasseur JJ. Natural phosphate doped with KI in HMDS: a mild and efficient reagent for alkylation and glycosylation of nucleobases. Nucleosides, Nucleotides & Nucleic Acids. 24: 1093-5. PMID 16248098 DOI: 10.1081/Ncn-200059179 |
0.206 |
|
2005 |
Zahouily M, Elmakssoudi A, Mezdar A, Rayadh A, Sebti S, Lazrek HB. Three Components Coupling Catalysed by Na2CaP2O7: Synthesis of α-Amino Phosphonates Under Solvent-Free Conditions at Room Temperature Letters in Organic Chemistry. 2: 428-432. DOI: 10.2174/1570178054405887 |
0.203 |
|
2008 |
Kurzrock R, Kantarjian HM, Blascovich MA, Bucher C, Verstovsek S, Wright JJ, Pilat SR, Cortes JE, Estey EH, Giles FJ, Beran M, Sebti SM. Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 509-14. PMID 18223226 DOI: 10.1158/1078-0432.Ccr-07-1532 |
0.202 |
|
2000 |
Kotharé MA, Ohkanda J, Lockman JW, Qian Y, Blaskovich MA, Sebti SM, Hamilton AD. Development of a tripeptide mimetic strategy for the inhibition of protein farnesyltransferase Tetrahedron. 56: 9833-9841. |
0.202 |
|
2006 |
Bazi F, Badaoui HE, Sokori S, Tamani S, Hamza M, Boulaajaj S, Sebti S. Transesterification of Methylbenzoate with Alcohols Catalyzed by Natural Phosphate Synthetic Communications. 36: 1585-1592. DOI: 10.1080/00397910600591508 |
0.201 |
|
2005 |
Badaoui HE, Bazi F, Tahir R, Lazrek HB, Sebti S. Synthesis of 3,4-dihydropyrimidin-2-ones catalysed by fluorapatite doped with metal halides Catalysis Communications. 6: 455-458. DOI: 10.1016/J.Catcom.2005.04.003 |
0.199 |
|
1996 |
Sebti SM, Hamilton AD. Rational design of Ras prenyltransferase inhibitors as potential anticancer drugs Biochemical Society Transactions. 24: 692-699. PMID 8878828 DOI: 10.1042/Bst0240692 |
0.198 |
|
2005 |
Zahouily M, Charki H, Abrouki Y, Mounir B, Bahlaouan B, Rayadh A, Sebti S. Natural Phosphate Modified with Sodium Nitrate: New Efficient Catalyst for the Construction of a Carbon-Sulfur and Carbon-Nitrogen Bonds Letters in Organic Chemistry. 2: 354-359. DOI: 10.2174/1570178054038830 |
0.195 |
|
1982 |
Sebti SM, Baird WM, Knowles BB, Diamond L. Benzo[a]pyrene-DNA adduct formation in target cells in a cell-mediated mutation assay Carcinogenesis. 3: 1317-1320. PMID 6817937 DOI: 10.1093/Carcin/3.11.1317 |
0.193 |
|
2006 |
Bazi F, Badaoui HE, Tamani S, Sokori S, Oubella L, Hamza M, Boulaajaj S, Sebti S. Catalysis by phosphates: A simple and efficient procedure for transesterification reaction Journal of Molecular Catalysis a-Chemical. 256: 43-47. DOI: 10.1016/J.Molcata.2006.04.034 |
0.189 |
|
2006 |
Peng H, Carrico D, Thai V, Blaskovich M, Bucher C, Pusateri EE, Sebti SM, Hamilton AD. Synthesis and evaluation of potent, highly-selective, 3-aryl-piperazinone inhibitors of protein geranylgeranyltransferase-I. Organic & Biomolecular Chemistry. 4: 1768-84. PMID 16633570 DOI: 10.1039/B517572K |
0.188 |
|
2012 |
Dakkach M, Atlamsani A, Sebti S. Le phosphate naturel modifié au vanadium : un nouveau catalyseur pour l’oxydation des cycloalcanones et des α-cétols en présence de l’oxygène moléculaire Comptes Rendus Chimie. 15: 482-492. DOI: 10.1016/J.Crci.2012.03.003 |
0.187 |
|
2021 |
Kazi A, Chen L, Xiang S, Vangipurapu R, Yang H, Beato F, Fang B, Williams TM, Husain K, Underwood PW, Fleming JB, Malafa MP, Welsh EA, Koomen JM, Trevino JG, ... Sebti SM, et al. Global Phosphoproteomics reveal CDK suppression as a vulnerability to KRAS addiction in Pancreatic Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33879459 DOI: 10.1158/1078-0432.CCR-20-4781 |
0.185 |
|
2011 |
Marchion DC, Cottrill HM, Xiong Y, Chen N, Bicaku E, Fulp WJ, Bansal N, Chon HS, Stickles XB, Kamath SG, Hakam A, Li L, Su D, Moreno C, Judson PL, ... ... Sebti S, et al. BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6356-66. PMID 21849418 DOI: 10.1158/1078-0432.CCR-11-0735 |
0.177 |
|
1992 |
Jani JP, Mistry JS, Morris G, Davies P, Lazo JS, Sebti SM. In vivo circumvention of human colon carcinoma resistance to bleomycin. Cancer Research. 52: 2931-7. PMID 1374681 |
0.173 |
|
1996 |
Vogt A, Qian Y, McGuire TF, Hamilton AD, Sebti SM. Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts Oncogene. 13: 1991-1999. PMID 8934546 |
0.168 |
|
1991 |
Sebti SM, Jani JP, Mistry JS, Gorelik E, Lazo JS. Metabolic inactivation: a mechanism of human tumor resistance to bleomycin. Cancer Research. 51: 227-32. PMID 1703034 |
0.165 |
|
1995 |
Pei Z, Calmels TPG, Creutz CE, Sebti SM. Yeast cysteine proteinase gene ycp1 induces resistance to bleomycin in mammalian cells Molecular Pharmacology. 48: 676-681. PMID 7476893 |
0.161 |
|
1994 |
Mcguire TF, Xu XQ, Corey SJ, Romero GG, Sebti SM. Lovastatin Disrupts Early Events in Insulin Signaling: A Potential Mechanism of Lovastatins Anti-Mitogenic Activity Biochemical and Biophysical Research Communications. 204: 399-406. PMID 7524501 DOI: 10.1006/Bbrc.1994.2472 |
0.152 |
|
2013 |
Urlam MK, Pireddu R, Ge Y, Zhang X, Sun Y, Lawrence HR, Guida WC, Sebti SM, Lawrence NJ. Development of new N-arylbenzamides as STAT3 dimerization inhibitors Medchemcomm. 4: 932-941. DOI: 10.1039/c3md20323a |
0.151 |
|
1991 |
Morris G, Mistry JS, Jani JP, Sebti SM, Lazo JS. Cysteine proteinase inhibitors and bleomycin-sensitive and -resistant cells. Biochemical Pharmacology. 41: 1559-66. PMID 1710457 DOI: 10.1016/0006-2952(91)90154-W |
0.145 |
|
1994 |
Weng W, Reynolds IJ, Jani JP, Blaskovich M, Sebti SM, Davies P, Pitt BR. Desensitization of 5HT2 receptors by protein kinase C activation in distal pulmonary vascular smooth muscle cells in culture. Microcirculation (New York, N.Y. : 1994). 1: 129-35. PMID 8790584 DOI: 10.3109/10739689409148268 |
0.143 |
|
1992 |
Morris G, Mistry JS, Jani JP, Mignano JE, Sebti SM, Lazo JS. Neutralization of bleomycin hydrolase by an epitope-specific antibody. Molecular Pharmacology. 42: 57-62. PMID 1378925 |
0.143 |
|
2021 |
Pidala J, Walton K, Elmariah H, Kim J, Mishra A, Bejanyan N, Nishihori T, Khimani F, Perez L, Faramand RG, Davila ML, Nieder ML, Sagatys EM, Holtan SG, Lawrence NJ, ... ... Sebti SM, et al. Pacritinib combined with sirolimus and low-dose tacrolimus for GVHD prevention after allogeneic hematopoietic cell transplantation: Preclinical and Phase I trial results. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33753457 DOI: 10.1158/1078-0432.CCR-20-4725 |
0.133 |
|
1997 |
Finder JD, Litz JL, Blaskovich MA, McGuire TF, Qian Y, Hamilton AD, Davies P, Sebti SM. Inhibition of protein geranylgeranylation causes a superinduction of nitric-oxide synthase-2 by interleukin-1beta in vascular smooth muscle cells. The Journal of Biological Chemistry. 272: 13484-8. PMID 9153192 DOI: 10.1074/Jbc.272.21.13484 |
0.132 |
|
1989 |
Sebti SM, Mignano JE, Jani JP, Srimatkandada S, Lazo JS. Bleomycin hydrolase: Molecular cloning, sequencing, and biochemical studies reveal membership in the cysteine proteinase family Biochemistry. 28: 6544-6548. PMID 2477059 |
0.131 |
|
1984 |
Sebti SM, Baird WM. Rat liver homogenate (S9)-mediated binding of benzo[a]pyren to DNA in V79 cells, V79 cell nuclei and aqueous solution Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis. 125: 307-314. PMID 6321977 DOI: 10.1016/0027-5107(84)90080-0 |
0.129 |
|
1992 |
Mistry JS, Jani JP, Morris G, Mujumdar RB, Reynolds IJ, Sebti SM, Lazo JS. Synthesis and evaluation of fluoromycin: a novel fluorescence-labeled derivative of talisomycin S10b. Cancer Research. 52: 709-18. PMID 1370650 |
0.124 |
|
2020 |
Boucher JC, Li G, Kotani H, Cabral ML, Morrissey D, Lee SB, Spitler K, Beatty NJ, Cervantes EV, Shrestha B, Yu B, Kazi A, Wang X, Sebti SM, Davila ML. CD28 co-stimulatory domain-targeted mutations enhance chimeric antigen receptor T-cell function. Cancer Immunology Research. PMID 33188139 DOI: 10.1158/2326-6066.CIR-20-0253 |
0.121 |
|
2003 |
Bazoui H, Zahouily M, Sebti S, Boulajaaj S, Zakarya D. Structure-cytotoxicity relationships for a series of HEPT derivatives. Journal of Molecular Modeling. 8: 1-7. PMID 12111397 DOI: 10.1007/s00894-001-0054-9 |
0.118 |
|
2022 |
Rhihil A, Aichi Y, Zahouily M, Sebti S, El Guendouzi M. Apatite phosphate doped by cobalt as hight efficient catalyst of multi-component synthesis of therapeutic spiropyrimidine compound. Natural Products and Bioprospecting. 12: 35. PMID 36121517 DOI: 10.1007/s13659-022-00359-8 |
0.115 |
|
1985 |
Sebti SM, Pruess-Schwartz D, Baird WM. Species- and Length of Exposure-dependent Differences in the Benzo(a)pyrene:DNA Adducts Formed in Embryo Cell Cultures from Mice, Rats, and Hamsters Cancer Research. 45: 1594-1600. PMID 3978626 |
0.114 |
|
1985 |
Sebti SM, Smolarek TA, Salmon CP, Baird WM. 7,12-Dimethylbenz[a]anthracene-DNA adduct formation in Wistar rat and Syrian hamster embryo cell cultures Chemico-Biological Interactions. 56: 1-12. PMID 3935336 DOI: 10.1016/0009-2797(85)90035-3 |
0.11 |
|
1984 |
Pruess-Schwartz D, Sebti SM, Gilham PT, Baird WM. Analysis of benzo(a)pyrene:DNA adducts formed in cells in culture by immobilized boronate chromatography Cancer Research. 44: 4104-4110. PMID 6331665 |
0.106 |
|
2012 |
Hidalgo-Carrillo J, Sebti J, Marinas A, Marinas JM, Sebti S, Urbano FJ. XPS evidence for structure-performance relationship in selective hydrogenation of crotonaldehyde to crotyl alcohol on platinum systems supported on natural phosphates. Journal of Colloid and Interface Science. 382: 67-73. PMID 22762986 DOI: 10.1016/j.jcis.2012.05.050 |
0.093 |
|
2008 |
Lazrek HB, Baddi L, Smietana M, Vasseur JJ, Sebti S, Zahouily M. One-pot synthesis of antiviral acyclovir and other nucleosides derivatives using doped natural phosphate as lewis acid catalyst. Nucleosides, Nucleotides & Nucleic Acids. 27: 1107-12. PMID 18788041 DOI: 10.1080/15257770802341285 |
0.087 |
|
2010 |
Hidalgo-Carrillo J, Sebti J, Aramendía MA, Marinas A, Marinas JM, Sebti S, Urbano FJ. A study on the potential application of natural phosphate in photocatalytic processes. Journal of Colloid and Interface Science. 344: 475-81. PMID 20129616 DOI: 10.1016/j.jcis.2010.01.020 |
0.071 |
|
2002 |
Burdelya L, Catlett-Falcone R, Levitzki A, Cheng F, Mora LB, Sotomayor E, Coppola D, Sun J, Sebti S, Dalton WS, Jove R, Yu H. Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone. Molecular Cancer Therapeutics. 1: 893-9. PMID 12481410 |
0.07 |
|
2014 |
Abrouki Y, Anouzla A, Loukili H, Bennazha J, Lotfi R, Rayadh A, Bahlaoui MA, Sebti S, Zakarya D, Zahouily M. Experimental Design-Based Response Surface Methodology Optimization for Synthesis of β-Mercapto Carbonyl Derivatives as Antimycobacterial Drugs Catalyzed by Calcium Pyrophosphate. International Journal of Medicinal Chemistry. 2014: 586437. PMID 25383218 DOI: 10.1155/2014/586437 |
0.06 |
|
1990 |
Lazo JS, Hoyt DG, Sebti SM, Pitt BR. Bleomycin: A pharmacologic tool in the study of the pathogenesis of interstitial pulmonary fibrosis Pharmacology and Therapeutics. 47: 347-358. PMID 1705351 DOI: 10.1016/0163-7258(90)90061-6 |
0.05 |
|
2012 |
Aitenneite H, El Bouari A, Sebti S, Saadi M, El Ammari L, Adil K. Poly[(μ(3)-hydrogenphosphato)(4H-1,2,4-triazole-κN(1))zinc]. Acta Crystallographica. Section E, Structure Reports Online. 68: m1426-7. PMID 23284388 DOI: 10.1107/S1600536812044182 |
0.042 |
|
2003 |
Zahouily M, Rhihil A, Bazoui H, Sebti S, Zakarya D. Structure-toxicity relationships study of a series of organophosphorus insecticides. Journal of Molecular Modeling. 8: 168-72. PMID 12858851 DOI: 10.1007/s00894-002-0074-0 |
0.035 |
|
1988 |
Sebti SM, Lazo JS. Metabolic inactivation of bleomycin analogs by bleomycin hydrolase Pharmacology and Therapeutics. 38: 321-329. PMID 2461572 DOI: 10.1016/0163-7258(88)90009-5 |
0.029 |
|
2000 |
Sebti SM. Guest editor Oncogene. 19: 6549. DOI: 10.1038/Sj.Onc.1204089 |
0.023 |
|
1994 |
Lazo JS, Sebti SM. Bleomycin Cancer Chemotherapy and Biological Response Modifiers. 15: 44-50. PMID 7540032 |
0.022 |
|
1991 |
Lazo JS, Sebti SM. Bleomycins Cancer Chemotherapy and Biological Response Modifiers. 12: 51-58. PMID 1718378 |
0.022 |
|
1990 |
Mistry JS, Sebti SM, Lazo JS. Separation of bleomycins and their deamido metabolites by high-performance cation-exchange chromatography. Journal of Chromatography. 514: 86-90. PMID 1698802 DOI: 10.1016/S0021-9673(01)89380-8 |
0.022 |
|
Hide low-probability matches. |